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Abstract 
Diabetes mellitus (DM) is a metabolic disorder affecting over 150 mi l l ion people 
worldwide. Around 90% of D M cases are classified as type 2，which is caused by 
partly pancreatic insulin deficiency and partly insulin resistance of peripheral tissues. 
One of the serious complications o f D M is foot ulceration, which could lead to 
amputations. Two Traditional Chinese Medicine (TCM) formulae were developed for 
treating diabetic foot ulcer and had shown promising effects in preliminary clinical 
study. In the present project, one of these formulae, the “ Q i Wei D i Huang Tang" (F2) 
and its eight individual herbs were investigated for their potential anti-diabetic 
effects w i th main focus on type 2 diabetes，using a systematic approach wi th various 
in vitro and in vivo models. 
Four in vitro models were employed for studying the effect o f herbal medicine 
on inhibiting intestinal glucose absorption, suppressing hepatic glucose production 
and enhancing peripheral tissues glucose uptake. Our results showed that F2 and all 
o f its individual herbs exhibited in vitro anti-diabetic effects wi th at least one of these 
mechanisms. Two of the individual herbs, Cortex Moutan and Rhizoma Alismatis 
showed the most promising effects in different in vitro studies. 
Potential anti-diabetic effects of Cortex Moutan and Rhizoma Alismatis aqueous 
Abstract i 
extracts were further investigated in vivo using neonatal-STZ type 2 diabetic rat 
model. With this model, basal glycaemia test and oral glucose tolerance test were 
performed. Our results showed that the two herbs did not exhibit any hypoglycemic 
or anti-hyperglycaemic activities. Preliminary studies also showed that F2 did not 
have any positive in vivo result. 
Despite of the negative in vivo results, our in vitro results obtained from BBMV 
(brush border membrane vesicles) revealed that the chloroform extract of Cortex 
Moutan aqueous extract showed very potent inhibitory effect on intestinal glucose 
absorption. Therefore, the hexane soluble fraction of Cortex Moutan ethanolic extract 
(CM-C) was further investigated。Our results showed that CM-C significantly 
inhibited glucose uptake in vitro. In addition, CM-C also significantly improved oral 
glucose tolerance in diabetic rats, but with only half of the activity of metformin (a 
common anti-diabetic drug) when both were tested at 200mg/kg body weight. 
f 
Through bioassay-guided fractionation, CM-C was found containing at least two 
compounds responsible for its in vitro anti-diabetic effect. Using mass spectrometry 
and nuclear magnetic resonance techniques, one of the compounds was confirmed to 
be paeonol, a known compound in Cortex Moutan. Preliminary in vivo studies 
showed that paeonol (at 200 or 400mg/kg) could slightly improve oral glucose 
tolerance after single dose, though the results did not reach statistical significance. 
Abstract i i 
To the best of our knowledge, this is the first report for the potential 
anti-hyperglycaemic effect of both Cortex Moutan crude extract and its compound 
paeonoL Future studies aim at exploring the potential use of paeonol as an 
anti-diabetic agent, further isolating other active components from Cortex Moutan, 
and also developing new anti-diabetic T C M formulae by screening herbs in a 
detailed systematic approach. 
-‘J 
Abstract iii 



































Abstract in Chinese 摘要 v 
Acknowledgements 
I would have to express my utmost gratitude to my supervisors, Prof. Clara B.S. 
Lau and Prof. Y.Y. Ho on the continuous guidance and help throughout the project 
and thesis preparation, and also to Prof. K.P. Fung and Prof. P.C. Leung for their 
support and advice. 
M y special thanks to our research team, Ms. K.M。Lau, Ms. Y.W. Chan, Mr. 
T.W. Lau, Mr. C.M. Chan and Ms. F.C. Lam. Without the team contributions 
towards the animal studies, it would have been an impossible task. I am also thankful 
to all staff of the Institute of Chinese Medicine, CUHK, especially Ms. K.L。Choi, 
Ms. S.W. Cheng and Mr. P.M. Hon for their great assistance in phytochemical 
studies. 
I would also like to express my thanks to Dr. Anthony E. James and his 
colleagues in the Laboratory Animal Service Centre, CUHK, for providing support 
towards animal studies; Dr. K.C. Choi of the School of Public Health, CUHK, who 
carried out statistical analysis; Dr. H. Cao of the National Engineering Research 
Center for Modernization of TCM (Zhuhai, Guangdong, China) for morphological 
authentication of herbs; and all people who have taken part in this project。Finally, I 
would like to take this opportunity to thank my family and friends for their support 
The work described in this thesis was substantially supported by a grant from the 
University Grants Committee of the Hong Kong Special Administrative Region, 
China under the Area of Excellence project "Chinese Medicine Research and Further 
Development" (Project No. AoE/B-10/01) coordinated by the Institute of Chinese 
Medicine of the Chinese University of Hong Kong. 
Acknowledgements vi 
Table of Contents 
Abstract i 
Abstract in Chinese 摘要 iv 
Acknowledgements vi 
Table of Contents vii 
List of Abbreviations xiii 
List of Figures xvi 




1.1 Epidemiology of Diabetes Mellitus 1 
1.2 Definition of Diabetes Mellitus 2 
1.3 Glucose Homeostasis and Diabetes Mellitus 2 
1.4 Classification of Diabetes Mellitus 5 
1.4.1 Type 1 Diabetes Mellitus 5 
1.4.2 Type 2 Diabetes Mellitus 6 
1.4.3 Other Specific Types 7 
1.4.4 Gestational Diabetes 9 
Table of Contents vii 
1.4.5 Clinical Stages of Diabetes 9 
1.5 Diagnostic Criteria of Diabetes Mellitus 10 
1.6 Complications of Diabetes Mellitus 12 
1.7 Pharmacological Treatment of Diabetes 13 
1.7.1 Treatment of Type 1 Diabetes 13 
1.7.2 Treatment of Type 2 Diabetes 14 
1.7.2.1 Sulphonylureas 17 
1.7.2.2 Biguanides 18 
1.7.2.3 a-Glucosidase Inhibitors 19 
1.7.2.4 Thiazolidinediones 20 
1.8 Diabetes and Traditional Chinese Medicine 21 
1.9 Project Objective 27 
Chapter 2 
Botanical and Phytochemical Studies 28 
2.1 Introduction 28 
2.2 Materials 31 
2.3 Authentication of Herbal Material 41 
2.3.1 Materials 41 
2.3.2 Phytochemical Studies 43 
2.3.2.1 Sample Preparation 43 
2.3.2.2 Thin Layer Chromatography 46 
2.3.3 Results 51 
2.4 Extraction of Herbal Material 56 
2.4.1 Materials and Methods 56 
Table of Contents viii 
5.7.2 Results 146 
2.5 Quantification of Sugar Content in Herbal Extracts 58 
2.5.1 Introduction 58 
2.5.2 Materials and Methods 58 
2.5.3 Results 61 
2.6 Discussion 65 
Chapter 3 
In vitro Studies on Formula 2 and its Individual Herbs 68 
3.1 Introduction 68 
3.2 Intestinal Glucose Absorption Studies 69 
3.2.1 Introduction 69 
3.2.2 Materials and Methods 70 
3.2.2.1 Preparation of B B M V 71 
3.2.2.2 B B M V Glucose Uptake Assay 72 
3.2.2.3 Bicinchoninic Acid (BCA) Protein Assay 73 
3.2.2.4 Preparation of Herbal Chloroform Extract 74 
3.2.2.5 Glucose Uptake Assay with Herbal Extracts 75 
3.2.3 Results 76 
3.3 Hepatic Gluconeogenesis Studies 79 
3.3.1 Introduction 79 
3.3.2 Materials and Methods 82 
3.3.2.1 Cell Culture 83 
3.3.2.2 Glucose Production Assay 83 
3.3.2.3 PEPCK Assay 85 
Table of Contents ix 
5.7.2 Results 146 
3.4 Cellular Glucose Uptake Studies 88 
3.4.1 Introduction 88 
3.4.2 Materials and Methods 89 
3.4.2.1 Cell Culture 89 
3.4.2.2 Differentiation of 3T3-L1 90 
3.4.2.3 2-Deoxy-D-glucose Uptake Assay ..91 
3.4.3 Results 92 
3.5 Discussion 96 
3.5.1 Intestinal Glucose Absorption Studies by B B M V 96 
3.5.2 Hepatic Gluconeogenesis Studies by H4IIE Cells 97 
3.5.3 Cellular Glucose Uptake Studies by Hs68 and 3T3-L1 Cells 99 
3.5.4 Conclusions 100 
Chapter 4 
In vivo Studies on Selected Herbs 103 
4.1 Introduction 103 
4.1.1 Animal Models of Type 2 Diabetes 103 
4.1.2 Chemically-induced Diabetic Models 104 
4.1.3 Neonatal-STZ Diabetic Rats 107 
4.2 Basal Glycaemia Test 109 
4.2.1 Animals 109 
4.2.2 Testing Method 110 
4.2.3 Results 112 
4.3 Oral Glucose Tolerance Test 114 
Table of Contents x 
4.3.1 Animals 114 
4.3.2 Testing Method 114 
4.3.3 Results 116 
4.4 Discussion 119 
Chapter 5 
Bioassay-guided Fractionation of Cortex Moutan 125 
5.1 Introduction 125 
5.1.1 Phytochemical Studies of Cortex Moutan 125 
5.2 Organic Extraction of Cortex Moutan 128 
5.2.1 Extraction Method 128 
5.2.2 Results ."••. 129 
5.3 BBMV Glucose Uptake Assay with Fraction CM-C 131 
5.3.1 Materials and Methods 131 
5.3.2 Results 131 
5.4 In vivo Studies of Fraction CM-C 133 
5.4.1 Materials and Methods 133 
5.4.2 Results 133 
5.5 Fractionation of Fraction CM C 137 
5.5.1 Materials and Methods 137 
5.5.2 Results 139 
5.6 BBMV Glucose Uptake Assay with CM-C Sub-fractions 142 
5.6.1 Results 142 
5.7 Isolation of Active Compound in Fraction CM-C4 144 
5.7.1 Materials and Methods 145 
Table of Contents xi 
5.7.2 Results 146 
5.8 Structure Elucidation of CM-C4a 148 
5.8.1 Materials and Methods 148 
5.8.2 Results 149 
5.9 Effect of Paeonol in Oral Glucose Tolerance Test 152 
5.9.1 Materials and Methods 152 
5.9.2 Results 153 
5.10 Discussion 155 
Chapter 6 
General Discussion 163 
6.1 Introduction 163 
6.2 Summary of Research Findings 164 
6.3 Limitations and Improvements 167 
6.4 Future Directions 169 
6.5 Conclusion 170 
Appendices 172 
Appendix 1 Low Resolution EI Mass Spectrum of Paeonol Reference... 173 
Appendix 2 Low Resolution EI Mass Spectrum of CM-C4a 174 
Appendix 3 High Resolution EI Mass Spectrum of Paeonol Reference .. 175 
Appendix 4 High Resolution EI Mass Spectrum of CM-C4a 176 
Appendix 5 ^H-NMR Spectrum of Paeonol Reference 177 
Appendix 6 ^H-NMR Spectrum of CM-C4a 178 
References 179 
Table of Contents xii 
List of Abbreviations 
^H-NMR Proton nuclear magnetic resonance 
2-DOG 2-Deoxy-D-glucose 
^H Trit ium 
ADP Adenosine diphosphate 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
B B M V Brush border membrane vesicles 
BCA Bicinchoninic acid 
cAMP Adenosine 3’,5'-cyclic monophosphate 
CDCI3 Deuterium chloroform 
CHCI3 Chloroform 
CUSO4.5H2O Copper(II) sulphate pentahydrate 
D M Diabetes mellitus 
D M E M Dulbecco's Modified Eagle Medium 
D N A Deoxyribose nucleic acid 
DTT Dithiothreitol “ 
EDTA Ethylenediaminetetraacetic acid 
EI Electron impact 
ELSD Evaporative light scattering detector 
EtOAc Ethyl acetate 
EtOH Ethanol 
F1 Formula 1, Tuo Du Sheng Ji Tang 
F2 Formula 2, Qi Wei Di Huang Tang 
List of Abbreviations xiii 
FBS Fetal bovine serum 
GDP Guanosine 5'-diphosphate sodium salt 
Glut Glucose transporter 
H2O Water 
H2SO4 Sulphuric acid 
HCl Hydrochloric acid 
HEPES 4-(2-Hydroxyethyl)piperazine-1 -ethanesulphonic acid 
HPLC High performance liquid chromatography 
i.p. Intraperitoneal 
i.v. Intravenous 
I B M X 3-Isobutyl-1 -methylxanthine 
I D D M Insulin-dependent diabetes mellitus 
IFG Impaired fasting glycaemia 
IGT Impaired glucose tolerance 
K+ Potassium ion 
KCl Potassium chloride 
KH2PO4 Monobasic potassium phosphate 
MeOH Methanol “ 
I 
M g Magnesium ion 
MgCl i Magnesium chloride 
MgS04 Magnesium sulphate 
MS Mass spectrometry 
Na+ Sodium ion 
Na2HP04 Dibasic sodium phosphate 
NaCl Sodium chloride 
List of Abbreviations xiv 
NAD+ Nicotinamide adenine dinucleotide 
N A D H Nicotinamide adenine dinucleotide (reduced form) 
NaF Sodium fluoride 
NaHCOs Sodium bicarbonate 
NaOH Sodium hydroxide 
NaSCN Sodium thiocyanate 
N I D D M Non-insulin-dependent diabetes mellitus 
NO Nitric oxide 
OGTT Oral glucose tolerance test 
PBS Phosphate buffered saline 
pCPT-cAMP 8-(4-Chlorophenylthio)adenosine 3’，5’-cyclic monophosphate 
PEPCK Phosphoenolpyruvate carboxykinase 
PPAR-y Peroxisome proliferators-activated receptor-gamma 
SEM Standard error of the mean 
SGLTI Sodium ion/D-glucose cotransporter 1 
STZ Streptozotocin 
TCM Traditional Chinese Medicine 
TLC Thin layer chromatography 
Tris Tris(hydroxymethyl)aminomethane 
JZD Thiazolidinediones 
UV Ultraviolet light 
V/HO World Health Organization 
XV 
List of Abbreviations 
List of Figures 
Fig. 1.1 Structure of Porcine Proinsulin 4 
Fig. 1.2 Structures of Examples of Oral Anti-Diabetic Agents 16 
Fig. 1.3 Structures of Some Anti-Diabetic Compounds Isolated from Herbs ..... 26 
Fig. 2.1 Photos of Raw Chinese Herbs Included in this Study 36 
Fig. 2.2 Structures of Known Anti-diabetic Compounds of Selected Herbs 40 
Fig. 2.3 Structures of Reference Compounds used in TLC Analysis 47 
Fig. 2.4 TLC Profile of Cortex Moutan.. 52 
Fig. 2.5 TLC Profile of Fructus Comi 52 
Fig. 2.6 TLC Profile of Fructus Schisandrae Chinensis 53 
Fig. 2.7 TLC Profile ofPoria 53 
Fig. 2.8 TLC Profile of Radix Astragali。……….。.….。…‘•....………。 54 
Fig. 2.9 TLC Profile of Radix Rehmanniae 54 
Fig. 2.10 TLC Profile of Rhizoma Alismatis …。 55 
Fig. 2.11 TLC Profile of Rhizoma Dioscoreae 55 
：。 
Fig. 2.12 Photo of Formula 2: “Qi Wei D i Huang Tang" 57 
Fig. 2.13 HPLC Chromatogram of Sugar Standards 62 
Fig. 2.14 Calibration Curves of Sugar Standards 63 
Fig. 3.1 Glucose Uptake Profile o f B B M V 77 
Fig. 3.2 Glucose Uptake of B B M V 78 
Fig. 3.3 The Gluconeogenesis Pathway 80 
Fig. 3.4 Gluconeogenic Activities of H4IIE 87 
Fig. 3.5 Oil red O staining of 3T3-L1 Cells 93 
Fig. 3.6 Cellular 2-Deoxy-D-glucose Uptake ofHs68 and 3T3-L1 .94 
List of Figures xvi 
Fig. 4.1 Structures of Diabetogenic Chemicals 105 
Fig. 4.2 Basal Glycaemia Test wi th Cortex Moutan and Rhizoma Alismatis ... 113 
Fig. 4.3 Oral Glucose Tolerance Test with Cortex Moutan. 117 
Fig. 4.4 Oral Glucose Tolerance Test with Rhizoma Alismatis 118 
Fig. 5.1 Structures of Compounds Found in Cortex Moutan 126 
Fig. 5.2 Organic Extraction Procedure of Cortex Moutan 130 
Fig. 5.3 Glucose Uptake of B B M V with CM-C Treatment 132 
Fig. 5.4 Basal Glycaemia Test with Fraction CM-C 134 
Fig. 5.5 Oral Glucose Tolerance Test with Fraction CM-C 136 
Fig. 5.6 Fractionation of CM-C 140 
Fig. 5.7 TLC Chromatogram of CM-C 1 to CM-C 15 Fractions 141 
Fig. 5.8 B B M V Glucose Uptake Assay with CM-C Sub-fractions 143 
Fig. 5.9 Preparative TLC Purification of Fraction CM-C4 147 
Fig. 5.10 Proton Assignment of Paeonol 。……151 
Fig. 5.11 Oral Glucose Tolerance Test with Paeonol…… ……154 
List of Figures xvii 
List of Tables 
Table 1.1 Other Specific Types of Diabetes 8 
Table 1.2 Diagnostic Criteria for Diabetes Mellitus 11 
Table 1.3 Frequency of Herb Usage in 345 Anti-diabetic T C M Formulae.... 23 
Table 1.4 Active Components of Anti-diabetic Chinese Herbs 25 
Table 2.1 Ingredients of Formula 1 and Formula 2 29 
Table 2.2 Voucher Specimen Numbers of Eight Chinese Herbs 42 
Table 2.3 TLC Conditions used for Authentication of Selected Herbs 。。。.…48 
Table 2.4 Extraction Yield of Selected Chinese Herbs 57 
Table 2.5 Conditions of HPLC-ELSD System for Sugar Quantification 60 
Table 2.6 Amount of Sugars in Herbal Extracts 64 
Table 3.1 Percentage Yield of CHCI3 Extraction of Herbal Aqueous Extracts …..。77 
Table 3.2 Summary of In vitro Studies of Formula 2 and its Individual Herbs …101 
Table 4.1 Characteristics of nO-STZ and n5-STZ Diabetic Rats 120 
Table 4.2 Dosages of Sugars Ingested after Taking Herbal Extracts 123 
Table 5.1 Peak Assignment of Mass Spectra of Paeonol Reference and CM-C4a …150 
Table 5.2 Proton Assignments of Paeonol Reference and CM-C4a 151 
List of Tables xviii 
Publications 
Lau, C. H , Chan, C. M,, Lau, T. W., Ho, Y. Y , Fung, K. R, Leung, P. C.and Lau, C. 
B. S. (2003). Pharmacological investigation on the anti-diabetic effect of Cortex 
Moutan. In Hong Kong Diabetes and Cardiovascular Risk Factors - East 
Meets West Symposium, p. 38. Hong Kong, China. 
Lau, C. H. (2004). Pharmacological investigation on the anti-diabetic effect of 
Cortex Moutan. In TWGHs - CUHK Eddie Wang Symposium on 
Complementary Chinese and Western Medicine — Integrated Approach, p. 113. 
Hong Kong, China. 
Publications xix 
Chapter 1 Introduction 
1.1 Epidemiology of Diabetes Mellitus 
"Diabetes Mell i tus" (DM), or “Diabetes，，in short, is a metabolic disorder 
affecting more than 150 mil l ion people (International Diabetes Federation, 2000)。 
Prevalence in developed and developing counties was 6.2% and 3.5% respectively in 
year 2000 (King et al., 1998). D M caused 1.7% of death worldwide in 2003, with 
death rate higher than stomach cancer, the second cancer kil ler (World Health 
Organization，2003). Majority of diabetic patients have type 2 D M ; only 5 to 10% are 
suffering from type 1 D M (Koda-Kimble and Carlisle, 2001). 
The prevalence of D M is increasing。It is expected that the adult population with 
diabetes w i l l be increased to 366 mi l l ion in 2030 (Wi ld et al., 2004). Developing 
countries w i l l be responsible for most of the increase due to changing to more 
sedentary life style, with high sugar and l ipid intake。 “ 
Situation in Chinese Populations 
Following India, China has the second largest diabetic population in the world。 
The adult diabetic population in China was 20.8 mil l ion in 2000, which wi l l be 
increased to 42.3 mil l ion in 2030 (Wild et al., 2004). In Hong Kong, diabetes is the 
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eighth disease killer, accounting for 2% of death in 2001 (Department of Health, 2003). 
The increase in prevalence of diabetes is leading to a huge impact on health and 
mortality in the future。 
1.2 Definition of Diabetes Mellitus 
The World Health Organization (WHO) published a report at 1999 for the 
definition, classification and diagnosis of diabetes mellitus. It defines diabetes 
mellitus as "a metabolic disorder of multiple aetiology characterized by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both" (World Health 
Organization, 1999). The word "Diabetes" refers to excessive urine excretion, while 
"Mell i tus" means the urine is "honeyed". Polyuria and glycosuria are well-known 
features of DM. 
1.3 Glucose Homeostasis and Diabetes Mellitus 
Glucose is the major energy source of human body and transported to the whole 
body through the bloodstream. Pancreas is the organ responsible for the regulation of 
blood glucose, by the action of two hormones: insulin and glucagon. The pancreas 
secretes insulin when blood glucose level is high, normally post-prandial, to inhibit 
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the endogenous glucose production and stimulate the glucose utilization and storage. 
As the blood glucose decreases, insulin release is inhibited and the pancreas releases 
glucagon, as the counter-regulatory hormone, to maintain the basal glucose level. 
Insulin is the glucose lowering hormone secreted by (3-cells in the islets of 
Langerhans of the pancreas. The islets of Langerhans are clusters of endocrine tissue 
scattered throughout the pancreas (Bonner-Weir, 1991). In addition to (3-cell which is 
the most common cell type, the islets also contain glucagon-producing a-cells, 
somatostatin-producing 5-cells, and pancreatic polypeptide-producing PP-cells. 
Insulin is originated from proinsulin, a single-chain protein. A connecting peptide (C 
peptide) is cleaved from proinsulin to form insulin (Fig. 1.1). In structure, insulin is a 
51 amino acid polypeptide with two peptide chains connected by two disulphide 
bonds (Rhodes, 2004). 
Along with basal insulin release, P-cells store insulin in granules. Increase of 
•w 
blood glucose level causes depolarization of p-cells. This results in influx of calcium 
ion and exocytosis of insulin containing granules, called the first phase of insulin 
release. Glucose also activates the protein kinase C, which is responsible for the 
sustained insulin release, called the second phase (Straub and Sharp, 2004). 
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Fig. 1.1 Structure of Porcine Proinsulin 
Insulin is originated from proinsulin, A connecting peptide (white area) is cleaved 
from proinsulin to form insulin (grey area). Insulin is a 51 amino acid polypeptide 
with two peptide chains connected by two disulphide bonds. 
(Extracted from Genuth, 1998) 
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The main targets of insulin are the liver, muscle and adipose tissue. In the liver, 
insulin decreases glucose production and increases glycolysis and glycogenesis. 
Similarly, it enhances glucose uptake, glycolysis and glycogenesis of muscle. For the 
adipose tissue, insulin increases the glucose uptake and the synthesis of triglycerides 
(Flakoll et al., 2004). Since these organs metabolize most of ingested glucose, defect 
of insulin production or action would lead to inability of lowering elevated blood 
glucose, which results in DM。 
1.4 Classification of Diabetes Mellitus 
Diabetes is formerly classified into "insulin-dependent diabetes mellitus" 
( IDDM) and "non-insulin-dependent diabetes mellitus" (NIDDM) by the treatment 
rather than pathogenesis。However, the WHO report in 1999 re-classified D M by the 
aetiological types in four categories: type 1, type 2, other specific types, and 
gestational diabetes (World Health Organization, 1999). 
1.4.1 Type 1 Diabetes Mellitus 
Type 1 D M results from total or nearly total destruction of pancreatic p-cells, 
mostly caused by autoimmune process. This type of diabetes is closely associated 
with certain types of histocompatibility antigens such as HLA-DR3 or HLA-DR4, 
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and also the presence of antibodies against islet cell, or glutamic acid decarboxylase 
(Koda-Kimble and Carlisle, 2001). Type 1 D M usually onsets in the early teenage 
years, mostly before 13 years old (Metcalfe and Baum, 1991). First-degree relatives 
of individuals with type 1 D M have an increased risk for developing diabetes. 
Due to complete destruction of insulin release, patients with type 1 diabetes are 
dependent on insulin to survive. They have more serious clinical presentation 
including glycosuria, polyuria, polydipsia, weight loss and ketoacidosis 
(Koda-Kimble and Carlisle, 2001)。 
1.4.2 Type 2 Diabetes Mellitus 
Type 2 D M is a result of insulin resistance and insulin secretory defect. Insulin 
resistance is decreased responsiveness of liver and peripheral tissues to insulin。This 
results in hyperglycaemia and stimulates the pancreas to produce more insulin. 
-1 
Therefore, hyperinsulinaemia is a common feature in patients with early insulin 
resistance. When (3-cells lose the ability to respond to elevated glucose over time, 
insulin secretion is impaired and blood glucose level becomes out of control, which 
is type 2 DM. Genetic factor, obesity, sedentary lifestyle and aging are the believed 
risk factors of insulin resistance and type 2 D M (World Health Organization, 1999). 
Chapter 1 Introduction 6 
The symptoms of type 2 D M are usually mi ld and onset gradually, including 
fatigue, polyuria and polydipsia. Lipolysis, weight loss and ketosis are uncommon 
due to the action of insulin. With the partially retained pancreatic function, early type 
2 D M could be controlled by diet, exercise and oral anti-diabetic drugs. However, as 
the situation becoming worse, insulin may be required to control the symptoms 
(Koda-Kimble and Carlisle, 2001). 
1.4.3 Other Specific Types 
This subclass comprises only approximately 1 to 2% of D M cases (Harris, 2004). 
Aetiologies for this class of D M include different types of genetic diseases, 
endocrine disorders, infections, side effects of drugs, and others. Some examples are 
listed in Table 1。1。 
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Table 1.1 Other Specific Types of Diabetes 
Aetiology Types Examples 
Genetic defects of p-cell function Chromosome 20, HNF4a 
Mitochondrial D N A 3243 mutation 
Genetic defects in insulin action Mutations of insulin receptor 
Diseases of the exocrine pancreas Pancreatitis 
Neoplasia 
Cystic fibrosis 
Endocrinopathies Cushing's syndrome 
Acromegaly 
Hyperthyroidism 
Drug or chemical induced Nicotinic acid 
Glucocorticoids 
Thyroid hormone 
Infections Congenital rubella 
•‘ I 
Cytomegalovirus 
Uncommon forms of immune- Insulin autoimmune syndrome -
mediated diabetes Anti-insulin receptor antibodies 
Other genetic syndromes Down's syndrome 
Huntington's chorea 
(Extracted from World Health Organization, 1999) 
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1.4.4 Gestational Diabetes 
Pregnancy could also result in impaired glucose tolerance (IGT) or 
hyperglycaemia, known as the “gestational diabetes". Although in most cases 
glucose tolerance returns to near-normal levels postpartum, the risk of developing 
IGT and type 2 D M for women with history of gestational diabetes is increased for 
lifetime (Buchanan et al,, 1998; Roseman et al, 1991). 
1.4.5 Clinical Stages of Diabetes 
Regardless of the underlying cause, D M is sub-divided into three classes with 
clinical stages: "Insulin requiring for survival", "Insulin requiring for control" and 
"Not insulin requiring”. The first one corresponds to " IDDM" , which patients are 
total or nearly total insulin deficient and depending on insulin injection to survive. 
The latter two constitute the “NIDDM，，，which means insulin is injected for better 
) ( 
glycaemic control, or blood glucose is controlled by non-pharmacological methods 
or drugs other than insulin. These patients are still possessing partial insulin action。 
In the development of D M from normal glucose homeostasis, there is often a 
state called "impaired glucose regulation”。It includes impaired fasting glycaemia 
(IFG) and IGT. IFG is characterized by elevated fasting blood glucose, while IGT is 
abnormal glucose regulation after meal. 
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1.5 Diagnostic Criteria of Diabetes Mellitus 
The WHO (World Health Organization, 1999) recommended two parameters for 
the diagnosis of diabetes, including the fasting plasma glucose level, and 2-hour post 
glucose load plasma glucose level (oral glucose tolerance) (Table 1.2). 
Fasting plasma glucose level is the most important diagnostic criteria for DM. 
Fasting plasma glucose lower than 6.1mM is considered as normal, while 7.0mM or 
above is considered as DM. IFG is plasma glucose level in between the two values. 
However, at least two test results showing hyperglycaemia are required for the 
diagnosis of D M for patients without obvious symptoms. Moreover, hyperglycaemia 
detected under stress such as infection could not be regarded as diagnostic of DM. 
I f the result of fasting plasma glucose level is not clear enough for the diagnosis 
of DM, an oral glucose tolerance test (OGTT) is recommended. The test is 
administrated in the morning after three days of unrestricted diet, followed by an 
overnight fasting of 8 to 14 hours. The subject should drink 75g of anhydrous 
glucose in 250 to 300ml water within five minutes. Plasma glucose level is 
determined after two hours. Normal people should have a value smaller than 7.8mM, 
while D M patients have a result of I L l m M or above. IGT is diagnosed i f the OGTT 
result is 7.8mM or above but smaller than l l . l m M 






























































































































































































1.6 Complications of Diabetes Mellitus 
Poorly controlled diabetic condition could lead to many complications and 
seriously affect various organs of the body. The common diabetic complications are: 
Diabetic eye disorder — Up to 12% of type 1 and 5% of type 2 diabetic 
patients lose their visions after 30 years of diabetes, as a result of diabetes 
retinopathy or cataract (Chew, 2004; Watkins et al, 2003). 
Diabetic nephropathy —- Diabetes could damage the glomeruli of the kidneys, 
leading to proteinuria and hyperuricaemia. Renal dialysis or transplantation is 
required at the end-stage (National Institute of Diabetes and Digestive and Kidney 
Diseases, 1995). 
Diabetic neuropathy — Possible clinical features of diabetic neuropathies 
include numbness, diarrhea, postural hypotension, respiratory arrests, sweating and 
erectile dysfunction (Watkins et aL, 2003). 
-1 
Cardiovascular disease - - Occurrence of cardiovascular disease is positively 
associated with the duration of diabetes. Macrovascular diseases are the major causes 
of morbidity and mortality in diabetic patients (Resnick et aL, 2004). 
Diabetic foot disorder — Peripheral neuropathy and vascular disease lead to 
numbness and ischaemia of foot. Unhealing ulceration could be caused by infection, 
leading to amputation in the worst cases (Watkins et al., 2003). Among all diabetic 
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patients, 15% of them would have foot problem during their lifetime (Palumbo and 
Melton, 1985). 
1.7 Pharmacological Treatment of Diabetes 
In order to improve the quality of life and reduce the risk of costly complications, 
tight control of blood glucose is critical for diabetic patients. Although dietary 
control and exercises are essential for glycaemic control, pharmacological treatments 
are often necessary for diabetic treatment. 
1.7.1 Treatment of Type 1 Diabetes 
For the treatment of type 1 DM, insulin is the only therapeutic agent used. The 
goal of insulin treatment is to maintain normoglycaemia with no hypoglycemic crisis. 
This requires a complete program of diabetes management including balance of 
-1 
carbohydrate intake, exercise, self-monitoring of blood glucose, and insulin 
adjustments based on these factors。Traditionally, insulin is administrated through 
subcutaneous injections. In order to achieve a similar pattern of normal insulin 
release, patients are required to have injection up to four times per day. As a result, 
some devices such as insulin pumps are designed for continuous insulin infusion to 
mimic normal insulin secretion. A meal plan should be designed to match the peak 
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action of injected insulin. 
The most common adverse effect of insulin is hypoglycaemia, caused by 
overinsulinization, skipped meals, exercise, defective counter-regulatory hormonal 
response or alcohol. Insulin may also cause lipohypertrophy and allergic reactions in 
the injection sites (Koda-Kimble and Carlisle, 2001). 
Apart from insulin, transplantation of pancreas or pancreatic islets is applied on 
type 1 diabetic patients requiring kidney transplant (Burke et al” 2004). Although the 
majority of pancreas transplant recipients have improved glycaemic control and 
enhanced quality of life (Gross et al., 2000), it should be noted that both the pancreatic 
transplant procedure and the immunosuppressive treatment for preventing rejection do 
carry considerable risks (Venstrom et al, 2003). 
1.7.2 Treatment of Type 2 Diabetes 
“t 
Type 2 diabetes could be controlled by dietary plan and exercise at early stage. 
Dietary plan could normalize plasma glucose and l ipid profile, and also achieve 
weight loss, while exercise could reduce cardiovascular risk factors, improve insulin 
sensitivity and enhance glucose uptake of skeletal muscle. However, i f 
non-pharmacological treatments fail to control diabetes, various classes of oral 
anti-diabetic drugs can be used。 
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Oral anti-diabetic drugs are the major treatment for type 2 diabetes. These drugs 
target on different organs involved in glucose metabolism and achieve glucose 
control by different modes of action, including a) stimulating insulin release; b) 
inhibiting hepatic gluconeogenesis; c) inhibiting carbohydrates absorption from 
intestine and d) improving insulin sensitivity of peripheral tissues. Sometimes, 
insulin is also used when the effect of oral agents are not satisfactory in late-stage 
diabetes. Currently, there are four major classes of clinically-used oral anti-diabetic 
agents, the sulphonylureas, biguanides, a-glucosidase inhibitors and 
thiazolidinediones. Structures of some commonly used anti-diabetic drugs are shown 
in Fig. 1.2. 
" 1 
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Fig. 1.2 Structures of Examples of Oral Anti-Diabetic Agents 
Sulphonylureas: (a) Chlorpropamide, (b) Tolbutamide, (c) Glyburide; 
Biguanides: (d) Metformin; 
a-Glucosidase inhibitors: (e) Acarbose; (f) Migl i tol ; 
Thiazolidinediones: (g) Rosiglitazone, (h) Pioglitazone. 
Chapter 1 Introduction 16 
1.7.2,1 Sulphonylureas 
Type 2 diabetes is the direct result o f insulin resistance and insulin secretory 
defect. Therefore, diabetic condition could be improved by stimulating the pancreatic 
insulin release. 
Sulphonylureas have been used in the management of type 2 diabetes for more 
than 40 years. Sulphonylureas stimulate insulin release of pancreatic P-cells and 
enhance the P-cells sensitivity to glucose (Zimmerman, 1997). A specific 
sulphonylurea receptor was found on the j3-cell, which is closely linked with the 
ATP-dependent K+ channel。Sulphonylureas inhibit this K+ channel and increase the 
intracellular K+ level P-Cells depolarize，leading to influx of calcium，and ultimately 
stimulating insulin release (Zimmerman, 1997). Examples of sulphonylureas include 
chlorpropamide, tolazamide, tolbutamide, glipizide, glyburide and glimepiride. 
The most common side effects of sulphonylureas are hypoglycaemia (So et al., 
- 1 
2002) and weight gain (Kabadi and Kabadi, 2003). Earlier sulphonylureas such as 
chlorpropamide was reported causing flushing reaction when taken with alcohol 
(Wolfsthal and Wiser, 1985). They would also induce syndrome of inappropriate 
antidiuretic hormone secretion by enhancing the release of antidiuretic hormone 
(Earley, 1971). 
Since sulphonylureas are effective only when some residual pancreatic p-cell 
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activity is present, they are not useful in type 1 diabetes. The drugs (except glyburide) 
are also not suitable for pregnant or breast-feeding women because they can cross the 
placenta and can be excreted into breast mi lk (Koda-Kimble and Carlisle, 2001). 
1.7.2.2 Biguanides 
Liver is the major organ for storing carbohydrates and producing glucose. 
Fasting blood glucose is mainly maintained by glucose from the liver。Therefore 
inhibition of hepatic glucose production could be a mode of action of anti-diabetic 
agents. Biguanides are believed to achieve the anti-diabetic effect by decreasing 
hepatic gluconeogenesis. 
The only biguanide available for human use is metformin。Unlike insulin and 
sulphonylureas, metformin lowers the blood glucose level without causing 
hypoglycaemia (Klepser and Kelly, 1997). Besides decreasing hepatic glucose output, 
metformin was also found improving insulin resistance, reducing plasma insulin 
level and improving the lipid profile (Bailey and Turner, 1996). However, the drug 
could cause gastrointestinal disturbances including diarrhea, abdominal discomfort 
and loss of appetite (Garber et al, 1997). More importantly, metformin treatment 
could lead to lactic acidosis by increasing lactate production in the gut and liver, and 
decreasing conversion of lactate to glucose (Bailey and Turner, 1996). Patients with 
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renal dysfunction, hepatic disease, or congestive heart failure should minimize the 
dosage since the risk of lactic acidosis is increased (Koda-Kimble and Carlisle， 
2001). 
1.7.2.3 a-Glucosidase Inhibitors 
Carbohydrates from food intake are the major source of blood glucose. 
Therefore, postprandial blood glucose could be controlled by inhibiting intestinal 
carbohydrates absorption. At least two kinds of a-glucosidase inhibitors were 
developed for this purpose, acarbose (Yee and Fong, 1996) and miglitol (Scott and 
Spencer, 2000). 
a-Glucosidases are enzymes located on the brush-border of the mucosa of the 
small intestine, digesting disaccharides into absorbable monosaccharides. The 
a-glucosidase inhibitors reversibly inhibit these enzymes and therefore lower 
postprandial blood glucose concentration. However, it should be noted that 
a-glucosidase inhibitors only work with a meal containing complex carbohydrates 
(Bischoff, 1994; Yee and Fong, 1996). 
For the adverse effects, a-glucosidase inhibitors often induce gastrointestinal 
effects such as flatulence, diarrhea and abdominal pain, which are due to 
fermentation of unabsorbed carbohydrates in the intestine (Chiasson et aL, 1994). 
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Moreover, using acarbose at a dose larger than 300 mg/day could increase the serum 
hepatic transaminases, indicating liver damage (Coniff et al., 1995). On the other 
hand, hepatotoxicity is not found for miglitol because it is not metabolized (Scott and 
Spencer, 2000). a-Glucosidase inhibitors should not be used on patients with 
malabsorption, inflammatory bowel disease, or intestinal obstruction. Patients taking 
high dose of acarbose should have monthly check in hepatic transaminases and stop 
taking the drug i f the levels increase (Koda-Kimble and Carlisle, 2001). 
1.7.2.4 Thiazolidinediones 
Insulin resistance is a common feature of type 2 diabetes。The thiazolidinedione 
(TZD) is a new class of anti-diabetic drug, which improve insulin sensitivity 
(Martens et al., 2002). The action is associated with stimulation of insulin receptor 
expression through the activation of peroxisome proliferators-activated 
-1 
receptor-gamma (PPAR-y), a transcription factor that is found mainly in adipose 
tissues (Martens et al., 2002). Troglitazone was the first available TZD but soon 
withdrawn from the market due to its hepatotoxic effect (Graham et al., 2003)。Two 
other TZD (rosiglitazone and pioglitazone) are still being used clinically (Norris et 
a/., 2003). 
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Hepatotoxicity is a serious side effect of TZD. Troglitazone has caused over 90 
cases of liver damage, which at least 68 were fatal and 10 required liver 
transplantation (Lee, 2003). Cases of hepatotoxicity were also reported for 
rosiglitazone (A1 Salman et al., 2000; Forman et al., 2000) and pioglitazone (Pinto et 
al., 2002). Therefore routine monitoring of serum hepatic transaminases is 
recommended for all TZD usage. Other side effects include decreases in 
haemoglobin and haematocrit, and edema caused by increased plasma volume 
(Henry, 1997). 
Since insulin is required for the TZD action, they are not used in type 1 diabetes。 
TZD should not be given to patients with elevated serum hepatic transaminases or 
severe congestive heart failure to avoid the risk of liver injury or edema 
(Koda-Kimble and Carlisle, 2001)。 
I 
1.8 Diabetes and Traditional Chinese Medicine 
Long before the invention of modem medicine, people in ancient China had 
developed their own systematic approach on human body. They recognized a specific 
disease called "Xiaoke"(、消渴)，making people suffering from great thirst, weight 
loss, and fluid loss by excreting large amount of urine. Description of Xiaoke could 
be traced back to the “Huang Di Nei Jing"(黃帝內,經，The Yellow Emperor's classic 
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of internal medicine) over 2000 years ago, as a disorder resulting from long-term 
consumption of fatty and sweet foods. Obviously, "Xiaoke" is what we refer as 
"Diabetes Mellitus" nowadays. In the view of Traditional Chinese Medicine (TCM), 
diabetes is caused by yin deficiency with dryness and heat. The treatment principle is 
thus to nourish yin, promote body fluids and clear fire. Herbs tonifying qi and 
warming the kidney are included when there is qi deficiency。Example of formulae 
with such functions include “Xiao Ke Fang"(消渴方，Xiaoke Prescription), "L iu 
Wei D i Huang Wan"(六味地黃九，Six-Flavour Rehmannia Pill), "Yu Nu Jian"(玉 
女煎，Jade Woman Decoction), and their modified formulae (Chen et al” 1993; 
Kuchinski, 1999). A recent paper reviewed 345 TCM formulae used on diabetic 
patients, and found that Radix Trichosanthis, Rhizoma Dioscoreae, Radix 
Rehmanniae and Radix Astragali are most common components in anti-diabetic 
formulae (Wu and Ren, 2002)。A list of herbs commonly used in anti-diabetic 
一 I 
formulae is shown in Table 1.3. 
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Table 1.3 Frequency of Herb Usage in 345 Anti-diabetic TCM Formulae 
Chinese Herbs Frequency 
天花粉 Radix Trichosanthis 175 
山藥 Rhizoma Dioscoreae 168 
生地黃 Radix Rehmanniae 159 
黃耆 Radix Astragali 140 
麥冬 Radix Ophiopogonis 117 
知母 Rhizoma Anemarrhenae 89 
五味子 Fructus Schisandrae Chinensis 88 
玄參 Radix Scrophulariae 74 
葛根 Radix Puerariae 74 
枸祀子 Fructus Lycii 73 
山茱英 Fructus Comi 72 
茯爷 Poria 68 
黃連 Rhizoma Coptidis 59 
熟地黃 Radix Rehmanniae Preparata 55 
I 
白 j f t Rhizoma Atractylodis Marcocephala 55 
衝寫 Rhizoma Alismatis 52 
丹參 Radix Salviae Miltiorrhizae 50 
牡丹皮 Cortex Moutan 49 
紅參 Radix Ginseng Rubra 47 
黨參 Radix Codonopsis 45 
(Extracted from Wu and Ren, 2002) 
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A lot of previous research work was found on studying the efficacy of 
anti-diabetic Chinese herbs. From these herbs, different classes of compounds with 
hypoglycaemic effect were isolated, including terpenoids, polysaccharides, 
flavonoids, alkaloids, etc. One example is berberine, an alkaloid isolated from 
Rhizoma Coptidis (黃連)，which the hypoglycaemic effect has been shown in 
various clinical studies in China (Chen and Xie, 1986; N i et al., 1988; Shi and Zhang, 
2000). A list of examples of anti-diabetic components extracted from Chinese herbs 
is shown in Table 1.4 (L i et al., 2004)。 
Not only Chinese people use herbal medicine for treating diabetes. Herbal 
treatment is also popular in many populations with their own traditional herbs 
(Eddouks et al, 2002; Lee et al., 2004; Singh et al., 2004). A good example of 
western anti-diabetic herb is the Goat's Rue {Galega officinalis), which has been 
used in medieval Europe. Its active component, the guanidine (Fig. 1.3d) was used to 
- 1 
synthesize several anti-diabetic compounds in the 1920s, leading to invention of 
biguanides (Bailey and Turner, 1996)。The story of biguanides suggests that plants 
could be a good source of new anti-diabetic agents. 
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Fig. 1.3 Structures of Some Anti-Diabetic Compounds Isolated from Herbs 
(a) Berberine, from Rhizoma Coptidis 
(b) Mangiferin, from Rhizoma Anemarrhenae 
- 1 
(c) Corosolic acid, from Folium Eriobotryae 
(d) Guanidine, from Galega officinalis 
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1.9 Project Objective 
With the increasing prevalence，diabetes and its related complications wi l l 
undoubtedly become a growing burden to the society。Most western anti-diabetic 
drugs target on type 2 diabetes, as it accounts for more than 90% of all diabetic cases. 
However, as previously mentioned, all these anti-diabetic drugs have their 
limitations and adverse effects, and hence it is important to identify new 
anti-diabetic agents. Since Chinese herbs have a long history in treating diabetes, 
they could be a good source of such agents。 
The objective of this project was to study the anti-diabetic effect of a Chinese 
herbal formula named "Qi Wei D i Huang Tang"(耆味地黃湯）and the individual 
components, wi th regards to type 2 diabetes. Various in vitro models for intestinal 
glucose absorption, hepatic glucose production and cellular glucose uptake were 
used to screen the selected herbs for their potential anti-diabetic effects. Herbs 
• -1 
showing promising effects in vitro were further investigated in vivo using diabetic 
rat model. Furthermore, bioassay-guided fractionation was employed in order to 
isolate the active component(s) and the chemical structure(s) was elucidated. It was 
hoped that those active component(s) isolated could be used for further development 
into new anti-diabetic agents. 
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Chapter 2 
Botanical and Phytochemical Studies 
2.1 Introduction 
In this chapter, the background information on the selected herbs is introduced. 
Furthermore, authentication and extraction of the herbs, and also the quantification 
of sugar content of herbal extracts are discussed. 
As mentioned in the last chapter, diabetic foot ulcer is a serious complication of 
D M which could lead to amputation. Chinese herbalists have long been credited 
with limb salvage in extensive diabetic foot ulceration, using simple daily surgical 
removal of dead tissue and herbal drinks for promoting healing (Shi and Zhou, 1996, 
1998). Two herbal formulae have been developed for treating diabetic foot ulcer, and 
being tested on patients: "Tuo Du Sheng Ji Tang"(托毒生肌湯）and "Qi Wei Di 
Huang Tang"(耆味地黃湯)，referred as Formula 1 (F l ) and Formula 2 (F2) 
respectively (Table 2.1; Wong et al., 2001). According to the TCM theory, F l is to 
strengthen the muscle and to control the swelling, while F2 is given to promote 
tissue regeneration. In a preliminary clinical study, these formulae were found to 
promote tissue granulation, and resulted in a rescue of 87% of legs from amputation 
when skin grafting was used in combination (Wong et al, 2001). 
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Table 2.1 Ingredients of Formula 1 and Formula 2 
"Tuo Du Sheng Ji Tang"(托毒生肌湯)，Formula 1 
Radix Astragali 黃耆 20g 
Radix Polygoni Mult i f lor i Preparata 帝(I首烏 9g 
Radix Rehmanniae 生地黃 9g 
Radix Stephaniae Tetrandrae 漢防已 9g 
Rhizoma Atractylodis Marcocephala 白 7[t 9g 
Rhizoma Smilacis Chinensis 菝葜 9g 
"Qi Wei Di Huang Tang，，（耆味地黃湯),Formula 2 
• “ • ‘ ‘ • ” •-•' • ‘ - • -•' • • • • ‘ - ‘ ‘ ‘ “ ‘ ' • “ - ' • • • • _ 'i ： ., • •„ - . ‘ ‘ • • s s s = 
Cortex Moutan 牡丹皮 6g 
Fructus Comi 山茱奥 9g 
Fructus Schisandrae Chinensis 五味子 6g 
Poria 获爷 6g 
-‘I 
Radix Astragali 黃耆 20g 
Radix Rehmanniae 生地黃 12g 
Rhizoma Alismatis 衝寫 6g 
Rhizoma Dioscoreae 山藥 9g 
(Extracted from Wong et al., 2001) 
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With the promising findings in the clinical study, F1 and F2 were further 
investigated for their potential anti-diabetic effects due to the fol lowing reasons: 
1. These formulae may possess anti-diabetic activity, as one of the modes 
of action in treating diabetic foot ulcer; 
2. Most of their individual herbs are frequently used in anti-diabetic TCM 
formulae, such as Radix Astragali and Radix Rehmanniae. Actually, 
nine out of the twelve herbs in F1 and F2 are of the “top 20” for using 
in anti-diabetic formulae (Table 1.3; Wu and Ren, 2002); 
3. As patients taking these formulae are normally taking western 
anti-diabetic agents，it is important to know i f these formulae also have 
hypoglycaemic effect and hence the dosage of western anti-diabetic 
drugs used may have to be altered. 
Since the anti-diabetic effect of F1 is being studied by another MPhil student, 
1 
the present project w i l l focus solely on the anti-diabetic effect of F2, and each of its 
eight individual herbs。 
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2.2 Materials 
Formula 2 consists of 8 herbs: Cortex Moutan, Fructus Comi, Fructus 
Schisandrae Chinensis, Poria, Radix Astragali, Radix Rehmanniae, Rhizoma 
Alismatis, and Rhizoma Dioscoreae. In this section, some information on the TCM 
theory and modem research findings with regards to diabetes on these herbs wi l l be 
discussed. 
Cortex Moutan 
Cortex Moutan (Mudanpi,牡丹皮，Fig. 2.1a) is the dried root bark of Paeonia 
suffruticosa of the family Ranunculaceae. In TCM theory, its action is to remove 
heat from blood, to activate blood circulation and eliminate blood stasis (State 
Pharmacopoeia Commission, 2000). Recent studies found that polysaccharides 
isolated from Cortex Moutan possessed hypoglycaemic effect on alloxan-induced 
•‘ I 
diabetic mice and streptozotocin (STZ, also known as streptozocin) -induced 
diabetic rats (Hong et al” 2003; Wang et al., 2001)。 
Fructus Corni 
Fructus Comi (Shanzhuyu,山茱英，Fig. 2.1b) is the dried ripe sarcocarp of 
Cornus officinalis of the family Comaceae. In TCM theory, its action is to replenish 
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the liver and kidney, restrain seminal discharge and relieve collapse (State 
Pharmacopoeia Commission, 2000). Ethanolic extract of Fructus Comi was found 
decreasing post-prandial blood glucose, increasing post-prandial insulin level and 
increasing the areas of pancreatic islet (Qian et al,, 2000). Ursolic acid (Fig. 2.2a) 
isolated from Fructus Comi showed anti-diabetic activity on STZ-induced diabetic 
rats (Yamahara et al., 1981). 
Fructus Schisandrae Chinensis 
Fructus Schisandrae Chinensis (Wuweizi,五味子，Fig. 2.1c) is the dried ripe 
fruit of Schisandra chinensis of the family Magnoliaceae. In TCM theory, its action 
is to arrest discharges, replenish qi, promote fluid secretion, tonify the kidney, and 
induce sedation (State Pharmacopoeia Commission, 2000). a-Glucosidase inhibitor 
was isolated from Fructus Schisandrae Chinensis, inhibited a-glucosidase in vitro 
一 I 
and decreased blood glucose level in alloxan-induced diabetic mice (Xu et al” 2001; 
Yuan et al, 2002). 
Poria 
Poria (Fil l ing,获爷，Fig. 2.Id) is the dried sclerotium of the fungus, Poria 
cocos of the family Polyporaceae. In TCM theory, its action is to cause diuresis, to 
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invigorate the spleen function, and to calm the mind (State Pharmacopoeia 
Commission, 2000). Dehydrotrametenolic acid (Fig. 2.2b) from Poria was found 
promoting adipocyte differentiation in vitro and improving oral glucose tolerance in 
db/db C57BLKS/J mice (Sato et al” 2002). Researchers also tried to mix Poria with 
steamed bun, which then given to type 2 diabetic patients twice a day. Decreases in 
both fasting and post-prandial blood glucose were observed after treatment (Cai and 
Shen, 2001). 
Radix Astragali 
Radix Astragali (Huangqi,黃耆，Fig. 2.1e) is the dried root of Astragalus 
membranaceus of the family Leguminosae. In T C M theory, its action is to reinforce 
qi and strengthen the superficial resistance, and to promote the discharge of pus and 
the growth of new tissue (State Pharmacopoeia Commission, 2000). Radix Astragali 
-1 
is extensively used in anti-diabetic T C M formulae (Wu and Ren, 2002), and also 
considered as the main component of F1 and F2 (Wong et al., 2001). Radix Astragali 
aqueous extract showed effect on preventing insulin resistance caused by tumor 
necrosis factor-alpha in normal rats (Lu et al., 1999). A study using STZ-induced 
diabetic mice found that the aqueous extract of Radix Astragali (up to the dose of 
160mg/kg) did not significantly decrease the blood glucose。However，it potentiated 
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the hypoglycaemic effect of fangchinoline, an active component of Radix Stephania 
(、漢防已)(Tsutsumi et al, 2003). Polysaccharides of Radix Astragali also decreased 
blood glucose and triglycerides, without effect on either insulin or C peptide level of 
STZ-induced diabetic rats (Lai et al., 2001). 
Radix Rehmanniae 
Radix Rehmanniae (Dihuang,地黃,Fig. 2. I f ) is the fresh or dried root tuber of 
Rehmannia glutinosa of the family Scrophulariaceae. The dried one is used in F2, 
known as "Sheng Dihuang"(生地黃，unprocessed Radix Rehmanniae). In TCM 
theory, action of dried Radix Rehmanniae is to reduce heat in blood, to nourish yin 
and promote the production of body fluid (State Pharmacopoeia Commission, 2000). 
Radix Rehmanniae is another herb commonly used in anti-diabetic formulae (Wu 
and Ren, 2002). Oligosaccharides of Radix Rehmanniae was found decreasing the 
- ‘( 
plasma glucose and increasing the hepatic glycogen and plasma insulin of 
alloxan-induced diabetic rats (Wang et al., 2003). Rehmaionoside D, a glycoside in 
Radix Rehmanniae, showed a dose-dependent trend on decreasing blood glucose of 
alloxan-induced diabetic rats (Yu et al, 2001)。 
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Rhizoma Alismatis 
Rhizoma Alismatis (Zexie，澤篇，Fig. 2.1g) is the dried tuber of Alisma 
orientalis of the family Alismataceae. In TCM theory, its action is to cause diuresis, 
and to remove damp-heat (State Pharmacopoeia Commission, 2000). Water-ethanol 
extract of Rhizoma Alismatis was found decreasing plasma glucose and triglycerides, 
and increasing plasma insulin of alloxan-induced and STZ-induced diabetic mice 
(Yang et 2002a, b)。 
Rhizoma Dioscoreae 
Rhizoma Dioscoreae (Shanyao,山藥，Fig. 2。lh) is the dried rhizome of 
Dioscorea opposite of the family Dioscoreaceae. In TCM theory, its action is to 
replenish the spleen and stomach, to promote fluid secretion and benefit the lung, 
and to strengthen the kidney and restrain seminal discharge (State Pharmacopoeia 
Commission, 2000)。Although Rhizoma Dioscoreae is frequently used in 
anti-diabetic formulae (Wu and Ren, 2002), reports on its anti-diabetic effect is few. 
It is reported that polysaccharides from Rhizoma Dioscoreae was found decreasing 
fasting and post-prandial serum glucose, and increasing C peptide level of 
alloxan-induced diabetic rats (Zhang et al., 2003). 
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Fig. 2.1 Photos of Raw Chinese Herbs Included in this Study 
(a) Cortex Moutan; (b) Fructus Comi 
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Fig. 2.1 Photos of Raw Chinese Herbs Included in this Study (Continued) 
(c) Fructus Schisandrae Chinensis; (d) Poria 
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Fig. 2.1 Photos of Raw Chinese Herbs Included in this Study (Continued) 
(e) Radix Astragali; (f) Radix Rehmanniae 
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Fig. 2.1 Photos of Raw Chinese Herbs Included in this Study (Continued) 
(g) Rhizoma Alismatis; (h) Rhizoma Dioscoreae 
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Fig. 2.2 Structures of Known Anti-diabetic Compounds of Selected Herbs 
(a) Ursolic add, from Fructus Comi; 
(b) Dehydrotrametenolic acid, from Poria 
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2.3 Authentication of Herbal Material 
2.3.1 Materials 
The eight raw herbs were purchased from a local supplier in Hong Kong and 
authenticated by a morphological expert, Dr. Cao Hui (National Engineering 
Research Center for Modernization of TCM, Zhuhai, Guangdong, China). For all 
eight herbs, herbarium voucher specimens were deposited at the museum of the 
Institute of Chinese Medicine, The Chinese University of Hong Kong, with the 
voucher specimen numbers shown in Table 2.2. 
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Table 2.2 Voucher Specimen Numbers of Eight Chinese Herbs 
Chinese Herbs Voucher Specimen Numbers 
Cortex Moutan 2003-2456 
Fructus Comi 2003-2461 
Fructus Schisandrae Chinensis 2003-2462 
Poria 2003-2454 
Radix Astragali 2003-2457 
Radix Rehmanniae 2003-2452 
Rhizoma Alismatis 2003-2455 
Rhizoma Dioscoreae 2003-2453 
-1 
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2.3.2 Phytochemical Studies 
Identities of eight selected herbs were confirmed by thin layer chromatography 
(TLC). The method for Cortex Moutan, Fructus Comi, Fructus Schisandrae 
Chinensis, Radix Astragali and Radix Rehmanniae were suggested by the Chinese 
Pharmacopoeia (State Pharmacopoeia Commission, 2000), using reference 
compounds as the standards. As the Chinese Pharmacopoeia did not provide any 
TLC identification method for Poria, Rhizoma Alismatis and Rhizoma Dioscoreae， 
the TLC system for these herbs were self-invented, using reference herbs as the 
standards. In addition, reference herb was also applied in the identification of 
Fructus Schisandrae Chinensis. 
2.3.2.1 Sample Preparation 
The sample preparation of each herb was mostly following that described in the 
-4 
Chinese Pharmacopoeia (State Pharmacopoeia Commission, 2000), unless not given. 
Cortex Moutan 
One gram of herb was grinded into powder and mixed with 10ml ether. After 
vortex for ten minutes, the mixture was filtered and dried using rotary evaporator 
and the residue was re-dissolved in 1ml acetone as test solution. 
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Fructus Corni 
One gram of herb was grinded into powder, refluxed with 20ml ether for four 
hours. The solution was filtered and dried using rotary evaporator. Residue was 
macerated with two quantities, each of 15ml petroleum ether (30-60。C) for about 
two minutes each time. The petroleum ether solution was discarded, and the residue 
was re-dissolved in ethanol-chloroform (3:2, v/v) by gentle heat as test solution. 
Fructus Schisandrae Chinensis 
One gram of herb was grinded into powder, refluxed with 20ml chloroform 
(CHCI3) for 30 minutes. The solution was filtered and dried using rotary evaporator. 
Residue was re-dissolve in 1ml chloroform as test solution. 
Poria 
-1 
Two grams of herb was grinded into powder, ultrasonicated with 5ml acetone 
for 30 minutes. The solution was filtered as test solution. 
Radix Astragali 
Three grams of herb was grinded into powder, refluxed with 20ml methanol 
(MeOH) for an hour. The solution was filtered and dried using rotary evaporator. 
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The residue was dissolved in 30ml of water and extracted with 20ml «-butanol 
saturated with water twice. The ^-butanol solutions were combined and washed with 
20ml water twice。Aqueous solution was discarded and the ^-butanol solution was 
dried by rotary evaporator and the residue was re-dissolved in 0.5ml MeOH as test 
solution. 
Radix Rehmanniae 
Two grams of herb was grinded into powder, refluxed with 20ml MeOH for an 
hour. The solution was filtered and evaporated using rotary evaporator until around 
5ml as test solution. 
Rhizoma Alismatis 
Five hundred milligrams of herb was grinded into powder, mixed with 20ml 
MeOH and ultrasonicated for 20 minutes. The solution was filtered and the filtrate 
was collected as test solution. 
Rhizoma Dioscoreae 
Six grams of herb was grinded into powder, mixed with 20ml MeOH-H〗。(1:1, 
v/v) and ultrasonicated for an hour. The solution was filtered and dried using rotary 
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evaporator. The residue was re-dissolved in 1ml MeOH as test solution. 
2.3.2.2 Thin Layer Chromatography 
For TLC analysis, the stationary phase used was silica gel 60 F254 on aluminum 
sheets (MERCK, Darmstadt, Germany). A l l reference compounds (Fig. 2.3) and 
reference herbs were purchased from the National Institute for the Control of 
Pharmaceutical and Biological Products (Beijing，China). For TLC analysis, 
standard solutions, mobile systems and detection methods were all listed in Table 
2.3. CHCI3，MeOH, ethyl acetate (EtOAc), ？2-biitanol, hexane, toluene and ether 
were purchased from Lab-Scan (Bangkok, Thailand). Acetone, formic acid, 
molybdatophosphoric acid and anisaldehyde were purchased from MERCK 
(Darmstadt, Germany). Sulphuric acid (H2SO4) was purchased from BDH 
Laboratory Supplies (Poole, UK)。Absolute ethanol (EtOH) was purchased from 
Panreac (Barcelona, Spain). Acetic acid was purchased from Riedel-de Haen (Seelze, 
Germany). 
Chapter 2 Botanical and Phytochemical Studies 46 
H 3 C - 0 \ A 八 H、C〇〇H 
T H〇， 
(a) 〇H (b) ‘ H 
( ^ H 
MeO OMe ' " " ' Y ^ O 
MeO X ； AuH / H 又三 
M e O y ^ W OH O ^ O H 
(C) \ (d) OH 
OH 
H三 
H O . A / 0 H 〇H 
I^H 
H O 〜 O 
(e) H〇z. 
Fig. 2.3 Structures of Reference Compounds used in T L C Analysis 
(a) Paeonol, for Cortex Moutan; (b) Ursolic acid, for Fructus Comi; 
(c) Deoxyschizandrin, for Fructus Schisandrae Chinensis; 
(d) Astragaloside IV, for Radix Astragali; (e) Catalpol, for Radix Rehmanniae 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































For each herb, sample solution and standard were applied on a TLC plate at the 
baseline using capillary tube, with 1cm space from the bottom edge of the plate. 
10ml of mobile phase was added to a covered glass chamber. After five minutes, 
when the chamber was pre-equilibrated with the mobile phase, the TLC plate was 
placed inside the chamber, and removed when the mobile phase reached a solvent 
front about 1cm below the top edge of the plate. The plate was dried, and visualized 
under ultraviolet light (UV), and/or after spraying with detection reagents. 
When a reference compound was used as the standard, a single spot should be 
developed in the chromatogram which corresponded in Rf value* and color to a spot 
found in the tested sample。When a reference herb was used as the standard, the 
chemical profile of tested sample and reference herb should be similar. 
Distance from baseline to centre of spot 
* Rf value = 
Distance from baseline to solvent front 
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2.3.3 Results 
Results of TLC analysis were shown in Fig. 2.4 to Fig. 2.11。Cortex Moutan, 
Fructus Comi, Fructus Schisandrae Chinensis, Radix Astragali and Radix 
Rehmanniae were identified using the corresponding reference compounds. Except 
Radix Astragali, these herbs were found containing compounds with the same Rf 
value of standard (shown in red boxes), and the identities were proven. Although a 
spot with similar Rf value to the reference compound was found in the chromatogram 
of Radix Astragali testing sample, the spot was relatively weak and not enough to 
confirm the identity of the testing sample. 
Reference herbs were used as the standard for the identification of Fructus 
Schisandrae Chinensis, Poria, Rhizoma Alismatis and Rhizoma Dioscoreae. Except 
Rhizoma Dioscoreae, all tested samples showed chemical profiles very similar to that 
of reference herbs, and the identities were proven. For the Rhizoma Dioscoreae, 
some spots of the tested herb were with similar Rf values to that of reference herb, 
but much weaker。Therefore it was difficult to make conclusion from the TLC 
analysis. 
Although the identity of Radix Astragali and Rhizoma Dioscoreae could not be 
proven by TLC analysis, their identities were confirmed morphologically. Therefore, 
all of the eight herbs were authenticated and used in the following biological studies. 
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Fig. 2.4 T L C Profile of Cortex Moutan 
~ Stationary Phase: Silica gel 60 F254； 
W ^ n r i i Mobile Phase: CHCls-MeOH-HiO (7:3:1); 
Rf = 0.64 y Detection: UV254nin. 
\ Key: I - Paeonol; I I - Tested herb 
‘ • \ Rf = 0.64 
I . . . 、 广 
I ^ ^ ^ ^ W ^ K J . - a ,糖 e • 
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Fig. 2.5 T L C Profile of Fructus Corni 
Stationary Phase: Silica gel 60 F254； 
Mobile Phase: Hexane-CHCls-EtOAc (20:5:8) 
Detection: (a) UV365nm; 
(b) 10% v/v H2SO4 in EtOH, 110。C for 5 minutes, visible light. 
Key: I - Tested herb; I I - Ursolic acid Chapter 2 Botanical and Phytochemical Studies 52 
I— _ _ 
Stationary Phase: Silica gel 60 F254； 
Mobile Phase: Ether-EtOAc-Formic acid (15:5:1); 
Detection: UV254nm. 
Key: I -Tested herb; I I - Reference herb; I I I - Deoxyschizandrin 
— R f = 0.39 
Rf = 0.37 




( a ) I H B I (b) 
I I I I I I 
Fig. 2.7 T L C Profile of Poria 
Stationary Phase: Silica gel 60 F254； 
Mobile Phase: CHCls-Acetone-Formic acid (20:6:0.5); 
Detection: (a) UV254nm; 
(b) 10% v/v H2SO4 in EtOH, 110。C for 5 minutes, visible light. 
Key: I - Tested herb; I I - Reference herb. 
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Fig. 2.8 T L C Profile of Radix Astragali 
Stationary Phase: Silica gel 60 F254； Mobile Phase: CHClg-MeOH-HzO (13:7:2) 
Detection: (a) UV365mn; 
(b) 10% v/v H2SO4 in EtOH, 110。C for 5 minutes, visible light. 
Key: I - Tested herb; I I - Astragaloside IV. 
、％ ； '女 
Fig. 2.9 T L C Profile of Radix Rehmanniae 
Stationary Phase: Silica gel 60 F254； 
Mobile Phase: CHCb-MeOEHHbO (14:6:1) 
Detection: Anisaldehyde TS, 105°C for 5 minutes, visible light. 
i 傲 K ^ - I - Tested herb; I I - Catalpol 
| P \ ^ Rf 二 0.23 、、. ^  Nv 
I I I I \ Rf = 0.23 
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静 Fig. 2.10 T L C Profile of Rhizoma Alismatis 
；... Stationary Phase: Silica gel 60 F254； 
i 條 Mobile Phase: Toluene-EtOAc-MeOH (8:1:1) 
_ ^ ^ Detection: 10% (w/v) molybdatophosphoric acid in EtOH, 110。C for 
霧 醒 5 minutes visible light 
^ ^ ^ p K ^ : I - Reference herb; I I - Tested herb 
-^ 
I I I 
Fig. 2.11 T L C Profile of Rhizoma Dioscoreae 
, Stationary Phase: Silica gel 60 F254； 
攀 Mobile Phase: Toluene-EtOAc-MeOH (8:1:1) 
舞 . 雄 Detection: 10% (w/v) molybdatophosphoric acid in EtOH, 110°C 
for 5 minutes, visible light 
權 
tKey: I - Tested herb; I I - Reference herb 
• u - i 
I I I I 
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2.4 Extraction of Herbal Material 
2.4.1 Materials and Methods 
For each individual herb, it was cut into small pieces and the weight was 
recorded. Disti l led water was added to cover the herb and refluxed for two hours. 
Extract solution was collected and herb was refluxed using fresh distilled water for 
another two hours. Solution of two extractions were combined, centrifuged at 
15000xg for lOmin, and filtered under vacuum by filter paper to remove 
un-dissolved components. Filtered solution was frozen, completely dried with 
freeze-drier and stored in desiccators. Weight o f dried extract was recorded and the 
extraction yield was calculated. 
Formula 2 was produced by the Hong Kong Institute o f Biotechnology Ltd, (Fig. 
2.12). Individual herbs were mixed in the stated ratio (Table 2.1) and extracted using 
water by reflux。Solution was spray-dried and stored in small packages of 5g each. 
-i 
2.4.2 Results 
Herbs were extracted by water and dried，with the percentage yield shown in 
Table 2.4. The percentage yield of herbs greatly varied, ranging from 2.3% of Poria 
to 47.0% of Radix Rehmanniae. Most herbs had the yield of 20% or above, except 
Poria, Rhizoma Alismatis and Rhizoma Dioscoreae. 
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Fig. 2.12 Photo of Formula 2: “ Q i Wei D i Huang Tang" 
Aqueous extract of Formula 2 in dried powder was produced by the Hong Kong 
Institute of Biotechnology Ltd. 
Table 2.4 Extraction Yield of Selected Chinese Herbs 
Chinese Herbs Percentage Yield 
Cortex Moutan 21.00 
Fructus Comi 39.17 
Fructus Schisandrae Chinensis 25.53 
Poria 2.33 
Radix Astragali 25.53 
Radix Rehmanniae 47.00 
Rhizoma Alismatis 9.83 
Rhizoma Dioscoreae 11.53 
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2.5 Quantification of Sugar Content in Herbal Extracts 
2.5.1 Introduction 
Carbohydrates are one of the major components of plants, serving as the energy 
source, energy storage, and structural elements. Since the presence of sugars in the 
herbal extract, especially glucose, could probably interfere with the in vitro and in 
vzVo studies, it is necessary to know the amount of sugar present in these herbal 
extracts. For such quantification analysis, high performance liquid chromatography 
(HPLC) was used together with evaporative light scattering detector (ELSD). 
2.5.2 Materials and Methods 
Standard Preparation 
Sugar standards were purchased from Sigma (St. Louis, MO, USA). Around 
30mg (accurately weighed out) L-Rhamnose (as the internal standard) was dissolved 
“‘t 
in 25ml water. D-glucose, D-fmctose and sucrose (each at around 20mg, accurately 
weighed out) were mixed and dissolved in 25ml water (stock solution). The stock 
solution was serial diluted by water according to these volume ratios: (stock 
solution:water) 1:24, 2:23, 5:20, 10:15, 15:10 and 25:0. Diluted solutions were added 
to six 10ml volumetric flasks respectively. Then, 1ml internal standard solution was 
added to each volumetric flask, and water was added to make up the volume of 10ml. 
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Sample Preparation 
For F2 and each herb, around lOmg (accurately weighed) of herbal aqueous 
extract (Section 2.4) was dissolved in 10ml water. Then, 5ml of sample solution was 
transferred to a 10ml volumetric flask, 1ml internal standard solution was added, and 
water was added to make up the volume. Solution was filtered by 0.45jim filter 
(Millipore, Billerica, Mass, USA) and the filtrate was ready for analysis. 
H P L C Quantif ication 
Sugars in each standard solution or each sample were analyzed with 
HPLC-ELSD for three times. The conditions of the HPLC-ELSD system were shown 
in Table 2.5. Peak areas of different sugars on the chromatogram were measured by a 
computer program “32 Karat Software version 5.0” (Beckman Coulter, Fullerton, CA, 
USA). Calibration curve was plotted using concentration ratio (e.g. concentration of 
一 t 
fructose / concentration of rhamnose) vs. peak area ratio (e.g. peak area of fructose / 
peak area of rhamnose)。For sample analysis, the sugar concentration in sample was 
determined by the peak area ratio using the calibration curve. 
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Table 2.5 Conditions of HPLC-ELSD System for Sugar Quantification 
HPLC Conditions 
Auto-sampler: Beckman (Fullerton, CA, USA) System Gold 508 
Autosampler 
Solvent pump: Beckman System Gold 125 Solvent Module 
Stationary phase: Alltech (Deerfield, IL, USA) Prevail Carbohydrate 
ES Column (5jim, 250mm x 4.6mm) 
Mobile phase: Acetonitrile (Lab-scan, Bangkok, Thailand) - water 
(7:3, v/v) 
Injection volume: 20jil 
Flow rate: Iml/min 
Running time: 20 min for standards, 30 min for testing solutions 
-^ 
ELSD Conditions 
— - - • • ‘ - -• • - ‘ ‘• ’ • … I •. • • _. 
Detector: Alltech ELSD 2000 
Temperautre: 80°C 
Nitogen gas flow: 2L/min 
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2.5.3 Results 
,Preliminary studies had been carried out with different sugar standards, finding 
that the L-rhamnose was a suitable internal standard as it was not found in all of the 
i 
tested herbs, and also with retention time that did not overlap with the studied sugars. 
The retention time of rhamnose, fructose, glucose and sucrose were around 5.0 min, 
6.1 min, 7.3 min and 9.0 min respectively (Fig. 2.13). Calibration curve of three 
sugars were shown in Fig. 2.14. Each calibration curve was not a complete straight 
line, and was fitted by quadratic regression (y == ax〕+ bx + c)，using the “32 Karat 
Software version 5.0". Since the sucrose content of Radix Astragali extract was out 
of the range of the standard curve，its amount was determined after five-fold dilution。 
The content of fructose, glucose, and sucrose in herbal extracts were quantified, 
as shown in Table 2.6. It was found that percentage weights of fructose in most 
herbal extracts were not exceeding 10% w/w, except that of Fructus Schisandrae 
•‘ i 
Chinensis and Fructus Comi. More than 10% w/w of glucose was also found in the 
extracts of these herbs, as well as in the Poria extract. For sucrose, it was abundantly 
found in the extracts of Cortex Moutan and Radix Astragali. From the total 
percentage weight of three sugars, it was found that extract of Radix Astragali, 
Fructus Comi and Cortex Moutan contained most simple sugars, while Rhizoma 
Alismatis and Rhizoma Dioscoreae contained the least. 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Most of the individual herbs in F2 are commonly used in many anti-diabetic 
formulae (Wu and Ren, 2002). A l l of the herbs were also previously reported for 
anti-diabetic effect, with crude extracts (Cai and Shen, 2001; Lu et al., 1999; Qian et 
al., 2000; Tsutsumi et al., 2003; Yang et al., 2002a, b) or active ingredients (Sato et 
al., 2002; Yamahara et al., 1981; Yu et al., 2001). However, for most of these herbs, 
the compound(s) responsible for the anti-diabetic effect are not yet known, and the 
mode of action remains unclear. Besides, the evidence of the anti-diabetic effect in 
certain herbs is weak as only single report was found. Therefore, further detailed 
investigations are necessary on their anti-diabetic effects using different in vitro and 
in vivo models. 
Before any pharmacological studies are performed, it is important to prove all of 
the raw herbal materials are genuine. Raw materials were authenticated by an expert 
on morphology, and further confirmed using TLC by comparing with corresponding 
reference compounds or reference herbs. Apart from morphological and TLC 
analysis, other authenticating methods such as microscopic study and HPLC analysis 
are also available. 
Traditionally, Chinese people usually boil the herbs with water and use the 
solution as medicine. Modernized TCM such as F1 and F2 are prescribed as dried 
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aqueous extract for better storage. Therefore, individual herbs of F2 were also 
extracted using water for the pharmacological studies。Except Poria, reasonable 
extraction yield was obtained in all o f the selected herbs, showing that the herbs 
contain water-soluble components. However, a low extraction yield was found in 
Poria and it may be due to the insoluble dietary fibers, as the major component of the 
herb (Cai and Shen, 2001). 
As plants are the major sources of carbohydrates in the diet, it is expected that 
the aqueous extract of selected herbs would also contain much sugar. Since the extra 
glucose from the herbal extracts could directly affect both the in vitro and in vivo 
studies, the content of glucose in herbal extracts was quantified. Sucrose content was 
also determined because in in vivo situation, sucrose can be broken down to glucose 
and fructose during digestive process。In addition, fructose content was also 
measured as it could be absorbed through the glucose transporter 5 (Glut5) in the 
- i 
small intestine (Ferraris, 2001). As the ripe fruit of plants, it was found that the 
extract of Fructus Schisandrae Chinensis and Fructus Comi contained most glucose 
and fructose. The percentage weight of glucose in Poria extract was also very high, 
due to the lack of other water-soluble components. Being the root of plants, sucrose 
was mainly found in Cortex Moutan, Radix Astragali and Radix Rehmanniae. The 
impact of these sugars on the in vitro and in vivo studies wi l l be discussed in the 
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fol lowing chapters。 
In the next two chapters, in vitro and in vivo investigations on potential 
anti-diabetic effects of F2 and the eight herbs were discussed 
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Chapter 3 
In vitro Studies on Formula 2 and its 
Individual Herbs 
3.1 Introduction 
As stated in the first chapter, the current pharmacological treatments of type 2 
diabetes mainly work by four different modes of action, including stimulating insulin 
release, inhibiting hepatic gluconeogenesis, inhibiting carbohydrates absorption from 
intestine, and improving insulin sensitivity of peripheral tissues. In order to study the 
potential anti-diabetic effects of F2 and its individual herbs, four in vitro models 
were employed which covered the following mechanisms of action: 
a) Brush border membrane vesicles (BBMV) - Inhibition of glucose 
absorption from the gut; 
b) Rat hepatoma cell line H4IIE - Inhibition of glucose production from liver; 
c) Human skin fibroblast cell line Hs68 and mouse 3T3-L1 adipocytes -
Stimulation of cellular glucose uptake by peripheral tissues. 
There are several advantages of using in vitro models for pharmacological 
investigations when comparing with using animal models or clinical studies. In vitro 
studies are usually easy to conduct, with fast results output, and use small amount of 
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testing samples, therefore suitable for screening pharmacological effects of large 
number of subjects. In vitro studies also allow specific investigations on certain 
pharmacological mechanisms. Furthermore, unlike animal and clinical studies, in 
vitro studies do not require ethical approvals. 
On the other hand, the major disadvantage of in vitro studies is that results 
obtained in vitro must be confirmed in vivo. This is because in vitro studies only look 
at the direct effects，bioavailability issues have not been taken into consideration。 
Also, due to the high specificities of in vitro models in mechanistic studies, several 
different in vitro models are required to cover the many possible pharmacological 
mechanisms, and hence four different in vitro models were chosen in the present 
study. 
3.2 Intestinal Glucose Absorption Studies 
I 
3.2.1 Introduction 
Carbohydrates by food intake are the major source of blood glucose. Since the 
small intestine is the major site of carbohydrates absorption, an in vitro model was 
used to study the inhibitory effect of herbal extracts on intestinal glucose absorption. 
Brush border membrane is found on the tips of the microvi l l i of small intestine. 
The membrane could be isolated by Mg2+ precipitation, and form tightly sealed 
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double-layer vesicle (Kessler et al., 1978), known as brush border membrane 
vesicles (BBMV). Since microvil l i are the active site of intestinal absorption, many 
membrane-bound transporters are found on BBMV. Over 90% of B B M V have right 
orientation, by the interior representing the serosal side (Haase et al., 1978), thus 
B B M V are able to absorb solute through corresponding transporter. Moreover, due to 
the lack of metabolic enzymes inside BBMV, solutes absorbed by B B M V are 
accumulated without being metabolized. As a result, B B M V are commonly used as 
an in vitro model to study intestinal absorption. 
The glucose uptake of B B M V is well-characterized. The transporter responsible 
for glucose absorption is the Na+/D-glucose cotransporter 1 (SGLTI), transporting 
two Na十 with one D-glucose molecule in the expense of ATP (Kessler et al., 1978; 
Semenza et al., 1984). Therefore, B B M V was chosen as the in vitro model for the 
study of intestinal glucose absorption. 
3.2.2 Materials and Methods 
The following chemicals were purchased from Sigma (St. Louis, MO, USA): 
potassium chloride (KCl), mannitol, 4-(2-hydroxyethyl)piperazine-1 -ethanesulphonic 
acid (HEPES), tris(hydroxymethyl)aminomethane (Tris), magnesium chloride 
(MgCl2), magnesium sulphate (MgS04), sodium thiocyanate (NaSCN), sodium 
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chloride (NaCl), phlorizin (phloretin 2'-glucoside, also known as phloridzin) and 
copper(II) sulphate pentahydrate (CUSO4.5H2O)。D-[2-^H]-glucose was purchased 
from Amersham (Litt le Chalfont, UK) . 
3.2,2.1 Preparation of BBMV 
B B M V was prepared based on the Mg2+ precipitation method (Kessler et al., 
1978; Schmitz et al, 1973). A rabbit was scarified and the small intestine was freshly 
dissected from the pyloric sphincter to ileocaecal junction。The small intestine was 
immediately placed in 200ml ice-cold 154mM KCL The mesentery and fat were 
removed, and the contents o f the intestine were gently squeezed out. The intestine 
was then cut longitudinally and washed thoroughly wi th KC l solution. After blotting 
dry between tissue papers，the intestine was wrapped with aluminum foi l and snap 
frozen in l iquid nitrogen. Frozen intestine was stored at -80。C. 
B B M V was prepared within one week after the dissection o f small intestine. 
Frozen small intestine was thawed in 200ml Buffer 1 ( lOmM mannitol, 2mM 
HEPES-Tris, pH 7.1) and was cut into small pieces. After mechanically vibrated for 
one minute, the solution was filtered under vacuum to remove connective tissues and 
muscles. Filtrate was made up to 300ml with Buffer L Then, 0.61g MgCl〗 was added 
to precipitate nuclei, mitochondria, most of basolateral membranes and other cell 
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debris. Solution was centrifuged at 4。C, 3800xg for 15 minutes. Pellet was discarded 
and the supernatant was further centrifuged at 4。C, 43000xg for 30 minutes. The 
pellet was resuspended in Buffer 2 (lOOmM mannitol, O. lmM MgS04, 2mM 
HEPES-Tris, pH 7.4), while supernatant was discarded. The solution was centrifuged 
at 4。C, 43000xg for 40 minutes and the pellet was resuspended in Iml Buffer 3 
(300mM mannitol, lOmM HEPES-Tris, O. lmM MgS〇4, pH 7.4). The volume of 
pellet was doubled using Buffer 3. The solution was passed through a 25 gauge 
needle five times to form vesicles. Solution containing B B M V was then divided into 
0.26ml aliquots and snap frozen in liquid nitrogen. 
3.2.2.2 BBMV Glucose Uptake Assay 
B B M V glucose uptake assay was performed based on the rapid filtration 
technique (Hopfer et al., 1973)。BBMV was thawed and resuspended in 0.44ml of 
Buffer 3. Twenty microliters of B B M V was mixed with 40}il of radiolabelled glucose 
solution (lOjiCi/ml D-[2-^H]-glucose, O.lmM D-glucose, lOOmM NaSCN, lOOmM 
mannitol, lOmM HEPES-Tris, pH 7.4). Glucose uptake was stopped after certain 
incubation times (0, 10, 20, 30, 40, 60, 120, 300 and 3600 seconds) by adding 1ml 
ice-cold stop-wash buffer (200mM NaCl, lOmM HEPES-Tris, 250|iM phlorizin, pH 
7.4), containing phlorizin as SGLTl inhibitor. The reaction mixture was rapidly 
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filtered through a pre-wetted 0。45|^ m cellulose, nitrate filter (Mill ipore, Billerica, 
Mass, USA) under vacuum。The filter was washed five times with 1ml stop-wash 
buffer to flush the non-specifically bound radiolabelled glucose. The filter, which 
retained the BBMV, was placed in a scintillation vial with 4ml OptiPhase HiSafe 2 
scintillation f luid (PerkinElmer life sciences, Inc., Boston, M A , USA). Radioactivity 
was counted by scintillation counter for one minute. The value of 0 second, 
representing the non-specific binding of glucose, was subtracted from all samples for 
the correction. 
The protein concentration of B B M V suspension was determined. One aliquot of 
frozen B B M V (0.26ml) was resuspended in 0.44ml of water. Ten-fold, 50-fold and 
100-fold dilutions (using water) were prepared, and the protein concentrations were 
determined by BCA assay (see below). Glucose uptake of B B M V was expressed as 
pmol glucose uptake per mg protein. 
‘i 
3.2.2.3 Bicinchoninic Acid (BCA) Protein Assay 
BCA Reagent A (Bio-Rad, Hercules, CA, USA) was mixed with Reagent B (4% 
CUSO4.5H2O) in a ratio of 50:1 to form the working BCA protein assay reagent. A 
serial of albumin standard (Sigma, St. Louis, MO, USA) from 1 Omg/ml to 
0.625mg/ml was prepared by two-fold serial dilution. Thirty microliters albumin 
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standard or sample was added to 96-well plate and 200|il BCA reagent was added to 
each well. After incubation at 37。C for 30 minutes, plate was read with Bio-Rad 
(Hercules, CA, USA) 3550 microplate reader at 540nm. Protein concentration of 
sample was determined by the calibration curve of albumin standard. 
3.2.2.4 Preparation of Herbal Chloroform Extract 
In this study, B B M V was used to investigate the effect of herbal extracts on 
intestinal glucose uptake. Since the glucose concentration in the final B B M V mixture 
was only 0.067mM, any glucose present in herbal extracts could lead to false positive 
results on inhibition of glucose uptake. Therefore, in order to get rid of glucose in 
herbal extracts, the aqueous extracts were further extracted by CHCI3 and only the 
CHCI3 extract was studied. This is because CHCI3 would not extract any glucose. 
However, the drawback was that many polar compounds were excluded in this assay. 
Each of the previously prepared herbal aqueous extract (F2 and its individual 
herbs, Section 2.4) was dissolved in distilled water at 200mg/ml. Equal amount of 
CHCI3 was added and mixed with the solution. The mixture was centrifuged at 
lOOOxg until a clear CHCI3 layer was separated from the water layer. The lower layer 
(CHCI3) was collected with a pre-weighed glass tube. Extraction was repeated two 
times and the CHCI3 solutions were combined. CHCI3 was completely dried by 
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nitrogen evaporator at 40。C. Weight of CHCI3 extract was recorded. 
3.2.2.5 Glucose Uptake Assay with Herbal Extracts 
Dried CHCI3 extracts were re-dissolved in distilled water by ultrasonication. 
Then, 20)il of B B M V was mixed with lOjil of 0.4mM radioactive glucose solution 
(40|iCi/ml D-[2-^H]-glucose, 0.4mM glucose, 400mM NaSCN, 400mM mannitol, 
40mM HEPES-Tris, pH 7.4) and 30|il of herbal CHCI3 extract. Glucose uptake was 
stopped after 20s incubation (peak of B B M V glucose uptake), by adding 1ml 
ice-cold stop-wash buffer. Glucose uptake of B B M V was measured as described in 
Section 3.2.2.2. For the screening purpose, all herbal extracts were tested at Img/ml. 
Dosage effects (0.25, 0.5 and LOmg/ml) were further investigated for those showing 
positive results. Three individual experiments were conducted for each herb with n=4 
each. 
For the statistical analysis, data were entered into and analyzed by using SPSS 
for Windows (version 11.5, SPSS Inc, Chicago, IL, USA). Mann-Whitney tests were 
used for comparisons of glucose absorption of B B M V between control group and 
each herbal extract treatment group. Statistical tests were two-sided, with a 
significant level of 0.05. 
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3.2.3 Results 
Different batches of B B M V were prepared. A typical glucose uptake profile of 
B B M V is shown in Fig. 3.1. The initial Na gradient across the membrane results in 
high transient accumulation of glucose at around 20 seconds (Kessler et al., 1978; 
Semenza et al, 1984). A batch of B B M V would only be used for experiments i f it 
showed the bell-shaped glucose uptake profile similar to Fig。3.1. 
Percentage yield of CHCI3 extraction of herbal aqueous extracts was shown in 
Table 3.1. The extraction yields were very low in all cases。Among all extracts, 
Cortex Moutan gave the highest yield of 3.7%, whereas most of the extraction yields 
were below 1%。 
Results of B B M V glucose uptake assay were shown in Fig. 3.2a. For 
anti-diabetic activity, inhibitory effects on glucose uptake were desirable. From the 
results, it was found that CHCI3 extract of F2 (Img/ml) significantly inhibited the 
glucose uptake of B B M V for For the individual herbs, Cortex Moutan most 
significantly inhibited glucose uptake of B B M V with 80% inhibition. Fructus 
Schisandrae Chinensis, Poria and Radix Astragali also significantly inhibited glucose 
uptake for around 30%. Rhizoma Alismatis and Rhizoma Dioscoreae showed 
significant inhibition, but lower than 20%. Fructus Comi and Radix Rehmanniae did 
not have any significant effect on B B M V glucose uptake. 
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Fig. 3.1 Glucose Uptake Profile of B B M V 
Table 3.1 Percentage Yield of CHCI3 Extraction of Herbal Aqueous Extracts 
Chinese Herbs Extraction Yield 
Formula 2 0.8% 
Cortex Moutan 3.7% 
- ‘ I 
Fructus Comi 0.5% 
Fructus Schisandrae Chinensis 1.1% 
Poria 0.2% 
Radix Astragali 0.2% 
Radix Rehmanniae 0.2% 
Rhizoma Alismatis 0.8% 
Rhizoma Dioscoreae 0.2% 
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Fig. 3.2 Glucose Uptake of B B M V 
(a) A l l herbs tested at 1 mg/ml; (b) Herbs tested with different concentrations. 
Results expressed as mean 土 SEM，n = 11 or 12. 
Significantly different from control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
Keys: A - Cortex Moutan B - Fructus Comi 
C - Fructus Schisandrae Chinensis D - Poria 
E - Radix Astragali F - Radix Rehmanniae 
G - Rhizoma Alismatis H - Rhizoma Dioscoreae 
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Those herbs with most promising results (inhibitory effect more than 25%) were 
further studied for the dosage effect (Fig. 3.2b). Inhibitory effects of all tested herbs 
were dosage dependent. Cortex Moutan gave nearly 50% inhibition at the lowest 
tested dose (0.25mg/ml). For Formula 2 and other tested herbs, the inhibitory effects 
at Img/ml were still lower than that of 0.25mg/ml Cortex Moutan extracts. 
3.3 Hepatic Gluconeogenesis Studies 
3.3.1 Introduction 
Gluconeogenesis is a process of synthesizing carbohydrates from 
non-carbohydrate sources. For higher animals, this process occurs largely in the liver, 
using pyruvate, lactate, glycerol and amino acids as precursors. A diagram of 
gluconeogenesis pathway is shown in Fig. 3.3. Three major enzymes are involved in 
gluconeogenesis, including phosphoenolpyruvate carboxykinase (PEPCK), 
fructose-1,6-bisphosphatase and glucose-6-phosphatase (Lehninger et al., 1993). 
Chapter 3 In vitro Studies on Formula 2 and its Individual Herbs .79 
Lactate 














Glycerol-3 -phosphate 1,3-Bisphosphoglycerate 
A 
T J 











Fig. 3.3 The Gluconeogenesis Pathway 
There are three major enzymes in gluconeogenesis, including phosphoenolpyruvate 
carboxykinase (PEPCK), fructose-1,6-bisphosphatase and glucose-6-phosphatase 
(Lehninger et al, 1993). 
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Since fasting blood glucose is mainly maintained by glucose from the liver, 
inhibiting hepatic glucose production could be a mode of action of anti-diabetic 
agents. H4IIE cells were used as the in vitro model for studying the effects of herbal 
extracts on hepatic gluconeogenesis. It is a cell line developed from rat hepatoma 
(Pitot et al., 1964; Reauber, 1961), and well-characterized in terms of the 
gluconeogenic activities. H4IIE retains the ability to convert lactate and pyruvate to 
glucose, by expressing gluconeogenic enzymes including glucose-6-phosphatase and 
PEPCK, in response to various hormones including insulin, cAMP and 
dexamethasone (Hombuckle et al, 2001; Sasaki et aL, 1984; Wang et al., 2000). 
Therefore, H4IIE is commonly used as an in vitro model of hepatic gluconeogenesis. 
In the present study, two assays were conducted with H4IIE, the glucose 
production assay and PEPCK assay. In the glucose production assay, dexamethasone 
and 8-(4-chlorophenylthio)-cAMP (pCPT-cAMP, a non-metabolized derivative of 
cAMP) was added to stimulate the gluconeogenic activity. Since insulin was able to 
counteract the activation, it was used as a positive control. Herbal extracts were 
added at different concentrations, to test i f they had any inhibitory effects. Pyruvate 
and lactate were provided as the precursors of glucose production. Glucose produced 
by the cells was measured by glucose oxidase method (Waltner-Law et al., 2002; 
Wang et al., 2000). Those herbs showing positive results in glucose production assay 
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were further studied by the PEPCK assay. Again, pCPT-cAMP and dexamethasone 
were added to stimulate the expression of PEPCK, and insulin was used as positive 
control. PEPCK activity was followed by the rate of N A D H consumption using 
spectrophotometric method (Wiese et al., 1991). 
3.3.2 Materials and Methods 
The following chemicals were purchased from Sigma (St。Louis, MO, USA): 
dibasic sodium phosphate (NasHPCU), monobasic potassium phosphate (KH2PO4), 
dexamethasone, insulin, pCPT-cAMP, glucose-free Dulbecco's Modified Eagle 
Medium (DMEM) without phenol red, sodium pyruvate, sodium lactate, 
ethylenediaminetetraacetic acid (EDTA), imidazole, sodium bicarbonate (NaHC〇3), 
phospohoenolpymvate, sodium fluoride (NaF), guanosine 5-diphosphate sodium salt 
(GDP), nicotinamide adenine dinucleotide (reduced form) (NADH), Tris, sodium 
hydroxide (NaOH), hydrochloric acid (HCl) and malate dehydrogenase. Cell culture 
reagents including DMEM, fetal bovine serum (FBS), penicillin-streptomycin 
mixture, trypsin-EDTA were purchased from Gibco BRL Life Technologies, Inc. 
(Carlsbad, CA, USA). Polyethylene glycol was purchased from BDH Laboratory 
Supplies (Poole, UK). Dithiothreitol (DTT) was purchased from Promega (Madison, 
WI, USA). 
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3.3.2.1 Cell Culture 
Rat hepatoma cell line H4IIE (American Type Culture Collection, ATCC, 
Manassas, VA, USA) was cultured in D M E M with 10% v/v FBS in a humidified 
incubator at 37。C with 5% CO2. Streptomycin (lOOjiig/ml) and penicillin (100 unit/ml) 
were added to prevent bacterial contamination. The medium was changed two to three 
times a week and cells were subcultured when the density reached 70%. To detach 
cells from the culture flasks, medium was discarded and culture flask was rinsed with 
phosphate buffered saline (PBS, containing 137mM NaCl, 2.7mM KCl, L5mM 
KH2PO4, S . lmM Na2HP04, pH7.4). Two milliliters of trypsin-EDTA was added and 
incubated at 37°C. After 5 min, medium was added to stop the reaction and the cells 
were ready to use. Cells were maintained between and passages for 
experiments. 
•‘ * 
3.3.2.2 Glucose Production Assay 
Gluconeogenic activity of H4IIE was measured by glucose production from 
pyruvate and lactate (Waltner-Law et al, 2002; Wang et al” 2000). Around 1.2 x 10^ 
cells were seeded in 90mm dishes. After growing for two days, medium was replaced 
by medium containing 500nM dexamethasone and 0.1 m M pCPT-cAMR Cells were 
divided into negative control group (full medium), positive control group (lOnM 
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insulin in ful l medium) and herbal treatment groups (herbal extracts dissolved in ful l 
medium, followed by sterilization using 0.22\im filter (Mill ipore, Billerica, Mass, 
USA)) and treated for five hours. Medium was then removed and dishes were 
washed three times with PBS. Two milli l iters glucose production buffer (glucose-free 
D M E M without phenol red, 5mM sodium pyruvate, 50mM sodium lactate) was 
added. After 3-hour incubation, 1ml of glucose production buffer was added to 0.3ml 
glucose assay solution (BioSystems, Barcelona, Spain), and incubated at 37。C for ten 
minutes. Absorbance at 500nm was recorded. Dishes were washed with PBS and 
cells were lysed by 5ml o fNaOH (0.5M) for ten minutes。The lysate was neutralized 
with 5ml HCl (0.5M). Protein content of samples was determined by BCA assay as 
previously described (Section 3.2.2.3). Amount of glucose production was corrected 
by protein amount. Results were expressed as the percentage of glucose production 
of negative control Three individual experiments with n二 1 were conducted for each 
-i 
herb. Since the sample size was small, statistical analysis was not applied due to 
inadequate power。It was because the test required large number of cells, and it was 
impractical to perform larger sample number for several herbs. 
Chapter 3 In vitro Studies on Formula 2 and its Individual Herbs .84 
3.3.2.3 PEPCK Assay 
PEPCK activity of H4IIE was measured by fol lowing the consumption of 
N A D H (Emoto et al, 1993; Wiese et al, 1991). Cells were seeded in 90mm dishes 
and treated as described in the glucose production assay. After 5-hour incubation 
wi th treatments, medium was removed and dishes were washed wi th PBS. Then, 
200)al of lysis buffer (20mM Tris-HCl, 50mM KCl, 5mM MgCl:, 2mM EDTA, I m M 
dithiothreitol and 1% polyethylene glycol，pH 6.6) was added to each dish. Cells were 
scrapped off, lysed with ultrasonication and centrifuged at ISOOOxg for five minutes. 
Pellet was discarded, and 50|li1 of supernatant was added to SOOjul PEPCK assay buffer 
( l l O m M imidazole-HCl, 45mM NaHCOs, 2mM phosphoenolpyruvate, 3mM MgS04, 
3mM MnCl2, 13mM NaF, I m M dithiothreitol, 0.5mM GDP, 0.15mM N A D H and 6 
units of malate dehydrogenase, pH 6.8) to measure PEPCK activity. Absorbance at 
340nm was monitored for one minute at 15-second intervals. Rate of absorbance change 
- i 
was recorded. Protein content of supernatant was determined by BCA assay as 
described in Section 3.2.2.3. Absorbance change was divided by protein content. 
PEPCK activity of each sample was expressed as percentage of negative control 
Three individual experiments with n=3 were conducted for each herb. For statistical 
analysis, two-sided Mann-Whitney tests were performed for comparisons of PEPCK 
activities between control and each treatment group, with a significant level of 0.05. 
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3.3.3 Results 
Results of glucose production assay were shown in Fig 3.4a. Insulin (act as 
positive control) inhibited glucose production of H4IIE to only 27% of control, and 
thus the model was validated. For all tested herbs, only Cortex Moutan (Img/ml, 
5mg/ml) and Rhizoma Alismatis (5mg/ml) showed consistent inhibitory effect on 
glucose production in three individual experiments. On the other hand, unfavorable 
stimulatory effects were found in F2 and other tested herbs. 
With the positive results in glucose production assay, the effects of Cortex 
Moutan and Rhizoma Alismatis on PEPCK activity were further studied. In Fig 3.4b, 
it was shown that only 5mg/ml Cortex Moutan significantly inhibited PEPCK 
activity, with a comparable effect to that of lOnM insulin. However, a slight 
stimulatory effect (8.5%) was found in Img/ml Cortex Moutan. No significant effect 
on PEPCK activity was found with Rhizoma Alismatis treatment. 
-i 
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Fig. 3.4 Gluconeogenic Activities of H4 I IE 
(a) Glucose production of H4IIE, n 二 3; (b) PEPCK activity of H4IIE, n = 8 or 9. 
Results expressed as mean 士 SEM. 
Significantly different from control: * p < 0.05, * * p < 0.01，*** p < 0.001. 
Keys: A - Cortex Moutan B - Fructus Comi 
C - Fructus Schisandrae Chinensis D - Poria 
E - Radix Astragali F - Radix Rehmanniae 
G - Rhizoma Alismatis H - Rhizoma Dioscoreae 
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3.4 Cellular Glucose Uptake Studies 
3.4.1 Introduction 
Apart from inhibition of the absorption and production of glucose, stimulation of 
the cellular glucose uptake in peripheral tissues is another possible mechanism to 
improve diabetic condition. Cellular glucose uptake is facilitated by a family of 
glucose transporters (Glut). Basal glucose uptake is mainly sustained by Glut l , 
which is non-insulin dependent. For Glut4, which is mainly found in muscles and 
adipose tissues, is stimulated by insulin. In the present study, two cell line models 
were employed for such investigations, including the human fibroblast cell line Hs68 
and mouse adipocytes 3T3-L1。 
Hs68 is a human foreskin fibroblast cell line developed from an apparently 
normal newborn male (Corcoran and Stetler-Stevenson, 1995). It provides a 
convenient model for studying the non-insulin dependent glucose uptake facilitated 
-1 
by Glut l (Gherzi et al., 1992). For 3T3-L1, it is a continuous substrain of 3T3 cell 
line, an embryonic fibroblast cell line isolated from Swiss albino mouse (Green and 
Meuth, 1974). Cells can undergo a pre-adipose to adipose like conversion as they 
progress from a rapidly dividing to a confluent and contact inhibited state (Green and 
Meuth, 1974). This process could be accelerated by 3-isobutyl-1 -methylxanthine 
( IBMX), dexamethasone and insulin. The glucose uptake of fully differentiated 
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3T3-L1 adipocytes are activated by insulin (Fong et al., 1991). 3T3-L1 adipocytes 
are commonly used in studies regarding insulin-dependent glucose uptake, facilitated 
by Glut4 (Chu et al., 2002; James et al., 2004). Uptake of glucose was measured by a 
glucose derivative, 2-deoxy-D-gluose (2-DOG), which accumulated in cells without 
being metabolized. Insulin was used as positive control for 3T3-L1, but not in Hs68 
studies since Glut l glucose transport was insulin-independent. 
3.4.2 Materials and Methods 
Dexamethasone, insulin, 3-isobutyl-1 -methylxanthine ( IBMX), oil red O, 
paraformaldehyde and 2-deoxy-D-glucose (2-DOG) were purchased from Sigma (St. 
Louis, MO, USA). Glucose-free D M E M was purchased from Gibco BRL Life 
Technologies, Inc. (Carlsbad, CA, USA). 2-Deoxy-D-[l-^H]-glucose was purchased 
from Amersham (Little Chalfont，UK)。 
3.4.2.1 Cell Culture 
The cell culture procedures for human skin fibroblasts Hs68 and mouse 
fibroblasts 3T3-L1 (ATCC, Manassas, VA, USA) were the same as H4IIE, as 
described in Section 3.3.2.1. For our study, Hs68 was maintained between and 
20th passages and 3T3-L1 was maintained between and passages. 
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3.4.2.2 Differentiation of 3T3-L1 
3T3-L1 fibroblast cells were chemically induced into differentiated adipocytes 
before experiments. Cells were seeded on the 24-well plates and maintained until 
after a confluent state for two days (set as day 0). On day 0, mediiiiri was switched to 
IBMX-DEX- IS cocktail medium (0.5mM I B M X , 0.5| iM dexamethasone and 5^g/ml 
insulin in complete D M E M , freshly prepared). On day 3, the IBMX-DEX- IS cocktail 
medium was switched to the complete medium supplemented wi th 5|ig/ml insulin. 
On day 5, the medium was then switched to normal medium ( D M E M with 10% FBS, 
100|Lig/ml streptomycin and 100 unit/ml penicillin). The cells were used in experiment 
between day 9 and day 12。 
Differentiation o f 3T3-L1 was confirmed by detection o f l ipid accumulation, 
using oi l red O to stain the neutral lipids accumulated in the cells. The cells were fixed 
with 2% paraformaldehyde. Oi l red O solution (3 volume of oi l red O saturated 
isopropanol solution mixed with 2 volume of water, freshly prepared) was added to 
the cells and it was allowed to stand at room temperature for 10 to 15 minutes. The 
cells were then washed extensively with PBS and observed under light microscope. 
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3.4.2.3 2-Deoxy-D-glucose Uptake Assay 
HS68 fibroblasts or 3T3-L1 adipocytes were grown to a confluent state in 
24-well plates. Prior to the uptake assay, Hs68 cells were glucose-starved by 
glucose-free D M E M for 1 hour; while 3T3-L1 cells were serum-starved for 2 hours. 
Cells were divided into negative control group (glucose-free DMEM), positive 
control group (only for 3T3-L1, lOOnM insulin in glucose free DMEM) or herbal 
treatment groups (herbal extracts dissolved in glucose-free DMEM, followed by 
filtration using 0.22jim filter (Mill ipore, Billerica, Mass, USA))。Cells were 
incubated with different treatments at 37°C for 30 min. The herbal treatment was 
then removed by washing with PBS for three times. Three hundred microliters 
radiolabeled 2-DOG mixture (2jiCi/ml 2-deoxy-D-[ 1 -^H]-glucose, 0.1 m M 2-DOG 
in glucose-free DMEM) was added and the reaction was allowed to proceed for 15 
min at 37°C. Reactions were then stopped by adding 1 ml/well of ice-cold lOmM 
- J 
2-DOG solution. Each well was washed by the same ice-cold lOmM 2-DOG solution 
twice. Then, lOOjil (for Hs68) or 200|il (for 3T3-L1) of 0.5M NaOH was added to 
lyse the cells, and the plates were put on the orbital shaker for 10 min to ensure 
complete lysis. Equal amount of 0。5M HCl was then added to neutralize the cell 
lysate. Then, 120|il (for Hs68) or 200|il (for 3T3-L1) of the cell lysate was 
transferred to scintillation vial and 4ml of OptiPhase HiSafe 2 scintillation fluid 
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(PerkinElmer, Boston, MA, USA) was added for radioactivity counting by liquid 
scintillation counter. Protein content of samples was determined by BCA assay as 
previously described (Section 3.2.2.3). Amount of 2-DOG uptake was corrected by 
protein amount. Results were expressed as the percentage of 2-DOG uptake of 
negative control. 
Three to four individual experiments with n=6 were conducted for each herb. 
For statistical analysis, two-sided Mann-Whitney tests were performed for 
comparisons of 2-DOG uptake between control and each type of treatments, with a 
significant level of 0.05. 
3.4.3 Results 
After chemical induction, about 90% of the 3T3-L1 cells showed an adipocytes 
phenotype by accumulation of lipid droplets, shown by oil red O staining (Fig. 3.5). 
-1 
Results of Hs68 and 3T3-L1 2-DOG uptake assay were shown in Fig 3.6. For 
both cell lines, increase in 2-DOG uptake was desirable for anti-diabetic effect. 
Chapter 3 In vitro Studies on Formula 2 and its Individual Herbs .92 
酬 纖 
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Fig. 3.5 Oi l red O staining of 3T3-L1 Cells 
Differentiation of 3T3-L1 was confirmed by detection of lipid accumulation, using 
oil red O to stain the neutral lipids accumulated in the cells, 
(a) Before chemical induction; (b) After chemical induction. 
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Fig. 3.6 Cellular 2-Deoxy-D-glucose Uptake of Hs68 and 3T3-L1 
(a) 2-DOG uptake of Hs68; (b) 2-DOG uptake of 3T3-L1. 
Results expressed as mean 土 SEM, n = 17 to 24. 
Significantly different from control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
Keys: A - Cortex Moutan B - Fructus Comi 
C - Fructus Schisandrae Chinensis D - Poria 
E - Radix Astragali F - Radix Rehmanniae 
G - Rhizoma Alismatis H - Rhizoma Dioscoreae 
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F2 significantly stimulated glucose uptake into Hs68 cells. For its individual 
herbs, all of them stimulated glucose uptake into Hs68 cells at different dosages, 
except Poria which did not show any significant effect at all tested concentrations. 
Fructus Schisandrae Chinensis, Rhizoma Alismatis and Rhizoma Dioscoreae 
stimulated glucose uptake at all tested concentrations. For Radix Astragali and Radix 
Rehmanniae, no significant effects were found at 0.01 mg/ml, while stimulating 
effects were found in higher dosages in a dose-dependent manner。Although Cortex 
Moutan and Fructus Comi showed stimulating effects at low concentrations, glucose 
uptake of Hs68 were inhibited at high concentrations (lO.Omg/ml), which is 
unfavorable for diabetic condition. 
For 3T3-L1, insulin significantly stimulated the 2-DOG uptake of the cells and 
validated the study。F2 significantly stimulated 3T3-L1 glucose uptake at 
concentrations of 0. Img/ml or over. For its individual herbs, all of them stimulated 
-1 
glucose uptake into 3T3-L1 cells at low dosages (l.Omg/ml or below) generally, 
except Rhizoma Dioscoreae which did not show any significant effect with all tested 
concentrations. No significant effect was found in Poria, Radix Rehmanniae, 
Rhizoma Alismatis at lOmg/ml, while Cortex Moutan, Fructus Comi, Fructus 
Schisandrae Chinensis, and Radix Astragali at this concentration were found 
inhibiting adipocytes glucose uptake, which were unfavorable effects. 
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3,5 Discussion 
3.5.1 Intestinal Glucose Absorption Studies by BBMV 
In the B B M V glucose uptake assay, the final glucose concentration in the 
reaction mixture was 0.067mM, or 0.012mg/ml in equivalent. Any extra glucose 
would reduce the absorption of radiolabelled glucose and result in false positive 
results. Even for Rhizoma Alismatis which contained the least glucose among all 
tested herbs (2.05%, w/w), it would still triple the glucose concentration in reaction 
mixture when its aqueous extract was used at Img/ml. Therefore, only the CHCI3 
soluble components in aqueous extracts were studied. Previous test using glucose 
oxidase method had confirmed that no glucose was extracted by CHCI3. 
However, for F2 and all 8 herbs, the yield of CHCI3 extraction was very low, 
indicating that most compounds in the aqueous extracts were excluded from the test. 
As there is no simple method to specifically exclude glucose and other sugars (which 
may also affect the glucose absorption), the use of B B M V on studying crude herbal 
aqueous extracts has its limitations. However, B B M V does play a role in the present 
study, as it helps to identify herbal components inhibiting intestinal glucose 
absorption. Among all tested herbs, Cortex Moutan showed an outstanding effect, 
suggesting that it might contain some potent components on inhibiting SGLTl in the 
small intestine. 
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Apart from studying the inhibitory effect on glucose transporters on BBMV, 
screening for the inhibition of a-glucosidases (enzymes which breakdown 
disaccharides into glucose during digestion) is also a possible approach to identify 
new compounds for reducing carbohydrate absorption (Choi et aL, 2000; K im et al., 
2004a). Alternatively, other in vitro models for studying intestinal transport may also 
be used. Examples include everted gut sac technique and the Ussing chamber, which 
can be used for detail investigations on the absorption of intestinal tissues (Acra and 
Ghishan, 1991). 
3.5.2 Hepatic Gluconeogenesis Studies by H41IE Cells 
It is interesting to note that most of tested herbs (except three herbs) stimulated 
the gluconeogenesis of the H4IIE cells. It is a new finding since none of the tested 
herbs have ever been reported to have such an effect. On the other hand, inhibitory 
-1 
effect on glucose production was found in Cortex Moutan (1.0 and 5.0mg/ml) and 
Rhizoma Alismatis (5.0mg/ml). At such high dose, cytotoxic effect may be a concern. 
However, cell death was not observed after treatments. In further mechanistic studies, 
it was found that only Cortex Moutan inhibited PEPCK activity but not Rhizoma 
Alismatis, indicating that the inhibition of glucose production by Rhizoma Alismatis 
is independent from PEPCK, and possibly related to other gluconeogenic enzymes 
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such as glucose-6-phosphatase. Besides, Fructus Comi also seemed to have slight 
inhibitory effect on glucose production of H4IIE, though, the results were not 
consistent in different experiments and therefore further studies are required in order 
to certain the results. 
In the H4IIE glucose production assay, medium containing herbal treatments 
was thoroughly washed of f by PBS before the glucose-free glucose production buffer 
was added. Therefore, glucose in herbal extracts would not affect the determination 
of glucose produced by the cells. However, since glucose may reduce the glucose 
production and PEPCK activity by feedback inhibition (Scott et al” 1998), additional 
glucose from herbal treatments may lead to false positive results. For Cortex Moutan 
and Rhizoma Alismatis, the only two herbs showed consistent positive effects on 
inhibiting H4IIE glucose production, their glucose concentrations were 7.79% w/w 
and 2.05% w/w respectively. When 5mg/ml (the highest dose tested) of these herbal 
-1 
extracts were used, glucose in medium (4.5mg/ml) was increased for 8.7% and 2.3% 
for Cortex Moutan and Rhizoma Alismatis respectively. Since the increase was less 
than 10%, it was unlikely that the observed positive results were false positive due to 
the additional glucose from herbal extracts. 
For further studying the effects of Cortex Moutan and Rhizoma Alismatis on 
gluconeogenesis, the effect on glucose-6-phosphatase activity of H4IIE could be 
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investigated. Studies on the gene expression of gluconeogenic enzymes could also be 
conducted (Waltner-Law et al, 2002; Wang et al, 2000). 
3.5.3 Cellular Glucose Uptake Studies by Hs68 and 
3T3-L1 Cells 
It was found that most of our tested herbs stimulated glucose uptake in both 
Hs68 and 3T3-L1 cells. We believe this is the first report on such effects. However, 
crude aqueous extracts of five other herbs (including Radix Ophiopogonis, Radix 
Ginseng, etc.) were previously reported to be able to stimulate 2-DOG uptake of 
3T3-L1 (Hong et a/., 2000). 
For the cellular 2-DOG uptake assays with Hs68 and 3T3-L1, the 2-DOG 
concentration used was very low (O.lmM), while aqueous extracts of tested herbs 
contain much higher concentration of glucose in comparison. However, since any 
-i 
additional glucose from herbal extracts would cause a reduction of the cellular 
uptake of 2-DOG, it would generate false negative rather than false positive results. 
Since our results showed that most herbal extracts stimulated the cellular uptake of 
2-DOG, additional glucose in herbal extracts was not a concern. However, for those 
herbs showing inhibitory effects on glucose uptake at high dosages (lO.Omg/ml), 
including Cortex Moutan, Fructus Comi, Fructus Schisandrae Chinensis and Radix 
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Astragali, most of them contained large amount of glucose (except Radix Astragali). 
Therefore, the competitive effect of glucose on 2-DOG absorption might need to take 
into account and hence the observed results might not be the true effect. 
As a further study on cellular glucose uptake, a physiological level of insulin 
could be added to all treatment groups, in order to mimic the in vivo situation. It 
would also allow the investigations in the potential effect of improving insulin 
sensitivity of peripheral tissues (Hong et al., 2000). 
3.5.4 Conclusions 
As mentioned in Chapter 2, previous reports on our tested herbs with regards to 
their potential anti-diabetic activities were mostly based on in vivo investigations, 
with very limited descriptions on the mechanisms. Therefore, our investigations 
attempted to provide additional information regarding their mechanisms of action to 
-i 
support previous in vivo findings. 
The results of in vitro studies were summarized in Table 3.2. In the first three 
assays (BBMV glucose uptake assay, H4IIE glucose production assay and H4IIE 
PEPCK assay), inhibitory effects were desirable for anti-diabetic agents. For the 
cellular glucose uptake of Hs68 and 3T3-L1, stimulatory effects were desirable. 




















































































































































































































































































































































































































































































































































































































The F2 exhibited inhibitory effect on glucose uptake of BBMV, and stimulatory 
effect on glucose production of H4IIE, and glucose uptake of Hs68 and 3T3-L1. For 
the individual herbs, six out of eight selected herbs showed significant inhibitory 
effects in the B B M V glucose uptake assay. On the other hand, five out of eight herbs 
showed undesirable effect to stimulate the glucose production o f H4IIE. In both 
cellular glucose uptake assays, only one herb was found with no significant effect at 
any tested dosages (Poria for Hs68 and Rhizoma Dioscoreae for 3T3-L1), and all of 
others stimulated glucose uptake of fibroblasts and adipocytes at different dosages. 
Apart from the above studied mechanisms, stimulation of insulin release is also a 
major pathway to improve diabetic conditions. Such investigations could be carried 
out in vitro using insulin-secreting cell line, such as hamster HIT-T15 (3-cells cell line 
(Noor et al, 1989). 
Among all tested herbs and F2, Cortex Moutan was the only one showing 
- 1 
desirable effects in all in vitro experiments, despite the inhibition of cellular glucose 
uptake at high doses. Another herb, Rhizoma Alismatis also showed promising 
effects in stimulating cellular glucose uptake, and also inhibiting hepatic glucose 
production in vitro. Therefore, these two herbs were selected for further in vivo 
investigations, using diabetic animal model. Details wi l l be discussed in the next 
chapter. 
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Chapter 4 
In vivo Studies on Selected Herbs 
4.1 Introduction 
Among F2 and its eight individual herbs, Cortex Moutan and Rhizoma Alismatis 
showed the most promising effects in the various in vitro models tested. Based on the 
results from in vitro studies, it is necessary to confirm the results in vivo. Therefore, 
studies using diabetic animal model were conducted in order to study the potential 
anti-diabetic effect o f the herbs。Animal studies had been approved by the Animal 
Experimentation Ethics Committee, CUHK (02/022/MIS)。 
4.1.1 Animal Models of Type 2 Diabetes 
In vivo studies related to D M have been carried out on many different animals, 
including non-human primates, dogs, cats，rats, mice, guinea pigs, rabbits and 
hamsters (Melby and Altman, 1976). Among these animals, mice and rats are the 
most commonly used, as the cost is lower and handling is easier. D M in animals 
could be a result o f genetic defects, or induced by chemicals. Both type 1 and type 2 
D M models were developed by these measures。In contrast to type 1 D M models 
which are usually with total insulin deficiency, type 2 D M models retain a certain 
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amount of insulin release, as well as insulin resistance. Most type 2 D M models are 
resulting from genetic defects. Some of them are monogenic (associated with a single 
gene), such as the db/db mice and Zucker fatty rats, while some are polygenic 
(associated with more than one gene), such as the Goto-Kakisaki rats (Mcintosh and 
Pederson, 1999). For those chemically-induced type 2 D M models, the pancreatic 
3-cdls are usually partially damaged by diabetogenic chemicals, resulting in 
insufficient insulin release and thus become diabetic. 
4.1.2 Chemically-induced Diabetic Models 
Alloxan (2,4,5,6-pyrimidmetetrone, Fig. 4。la) was a commonly used chemical to 
induce diabetes in animals (Szkudelski, 2001). Once the drug is absorbed by 
pancreatic (3-cells, it generates superoxide radicals by reacting with SH-containing 
cellular compounds. Excessive amount of the free radicals would seriously damage 
-1 
the DNA and stimulate the repair mechanism with the poly (ADP-ribose) polymerase。 
This leads to exhaustion of cellular NAD+ and ATP, and eventually causes cell death 
(Pieper et al., 1999). However, alloxan could also induce some side effects, as it 
causes damage to the liver, kidneys, and pituitary gland (Melby and Altaian, 1976). 
Therefore, alloxan had been replaced by another diabetogenic agent streptozotocin 
(STZ), as the principle agent used to induce diabetes in animals. 
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Fig. 4.1 Structures of Diabetogenic Chemicals 
(a) Alloxan; (b) Streptozotocin 
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Streptozotocin (STZ, 2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose, 
Fig. 4.1b) is a broad-spectrum antibiotic produced from Streptomyces achromogenes 
(Szkudelski, 2001). Comparing with alloxan, STZ has greater p-cells selectivity, 
lower mortality rate and also longer half-life in the body (Rodrigues et al., 1999). 
The use of STZ on inducing diabetes was first described in 1963 (Rakieten et al., 
1963). Once STZ is injected to animal, it is absorbed by the pancreatic P-cells 
through the glucose transporter 2 (Glut2) by its glucose moiety (Eisner et al., 2000; 
Schnedl et al., 1994; Thulesen et al” 1997). The cytotoxic effect on P-cells is carried 
out by several pathways. Methylation o f D N A is the main cause for the STZ-induced 
P-cell death, due to the carbonium ions (CH3+) generated by decomposition of the 
nitroso moiety of STZ (Eisner et al., 2000)。STZ also acts as a nitric oxide (NO) 
donor (Kwon et al, 1994), and the NO-induced DNA damage is proposed as another 
mechanism of ki l l ing p-cell (Kroncke et al, 1995; Pieper et al., 1999). Since the 
3-cell could be protected from STZ by inducing the expression of superoxide 
dismutase, a free radical scavenger, oxidative stress may also play a role on the 
cytotoxic effect of STZ (Szkudelski, 2001). Excessive DNA damage provokes the 
poly(ADP-ribose) polymerase, and the cells were killed due to exhaustion of NAD+ 
and ATP (Pieper et al, 1999). 
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4.1.3 Neonatal-STZ Diabetic Rats 
When STZ is injected to adult rats, it selectively damages p-cells, and generates 
type 1 D M model (Rodrigues et al, 1999). However, when STZ is used in new-bom 
rats on the first few days after birth, severe diabetes w i l l partially recover, leading to 
a mi ld to moderate diabetic condition in adult. It is due to the ability of neonatal rats 
to regenerate pancreatic P-cells, which only happens during the first few days of life 
(Wang et al., 1996). Since adult neonatal-STZ rats retain part of their p-cell activity, 
these rats are used as a model of type 2 diabetes。 
The neonatal-STZ rat model was first described in 1974, by intravenous (i.v.) 
injection of lOOmg/kg STZ on the day of birth (Portha et al., 1974). After that, 
several variations of the model were reported, such as using different dosages, 
different time of injection, and different routes of injection, and hence generating 
diabetic conditions with different severity and characteristics. The most commonly 
- i 
used neonatal-STZ models were induced on neonatal Wistar rats by intraperitoneal 
(i.p.) injection of STZ, including: (a) nO-STZ, lOOmg/kg STZ on day of birth; (b) 
n2-STZ, 90mg/kg STZ two days after birth; and (c) n5-STZ, 70mg/kg STZ five days 
after birth (Blondel et al., 1989; Fantus et al, 1987; Murali and Goyal, 2001; Tourrel 
et al, 2001), 
Chapter 4 In vivo Studies on Selected Herbs \ 107 
The ability to regenerate p-cells declines rapidly after birth。It was found that 
rats were unable to recover and survive when STZ was injected 7 days after birth 
(Cantenys et al” 1981). Therefore, more severe diabetic condition was observed in 
n5-STZ rats than n2-STZ and nO-STZ, indicated by higher non-fasting and fasting 
plasma glucose, higher glycosylated haemoglobin level, and poorer tolerance to 
glucose (Blondel et al‘, 1989). The insulin secretion triggered by glucose is defective 
in neonatal-STZ rats (Tsuji et al” 1993). The pancreatic insulin content of nO-STZ 
and n2-STZ is 50% of normal, while only 10% remains in n5-STZ rats (Blondel et 
a/” 1989). As an important characteristic of diabetes, insulin resistance was observed 
in n2-STZ and n5-STZ Wistar rats (Blondel et al” 1989; Fantus et al., 1987). 
However, insulin resistance was not found in nO-STZ (Blondel et al, 1989; Kergoat 
and Portha, 1985). 
In fact, there is a recent report on a new chemical-induced type 2 D M model, 
" I 
using i.p. injection of nicotinamide as a protective agent to P-cells, followed by i.v. 
injection of STZ, and moderate D M condition could be achieved (Novelli et al., 
2001). It was suggested that the insulin release of this nicotinamide-STZ model was 
more responsive to glucose, which is closer to human type 2 diabetes (Masiello et al., 
1998). However, this new model had not been fully validated. 
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When compared with those genetic models, neonatal-STZ model has greater 
flexibil ity for the severity of diabetic condition by altering the time of induction. 
Moreover, as normal rats are used for chemical induction, the cost for obtaining and 
maintaining the animals is much lower than that of genetic models. Therefore, 
neonatal-STZ model was chosen as the in vivo model in the present study。 
4.2 Basal Glycaemia Test 
Basal glycaemia test was performed to study the effect of herbs on the basal 
fasting plasma glucose. Since the test aimed at observing the glucose-lowering effect, 
n5-STZ Wistar rat was used as the animal model, for its higher basal glycaemia. 
Chemicals including streptozotocin, citric acid monohydrate, citric acid trisodium salt 
dihydrate, metformin and heparin were purchased from Sigma (St. Louis, MO, USA)。 
Glucose determination kit and lOOmg/dl (5.56mM) glucose standard were purchased 
-1 
from BioSystems (Barcelona, Spain)。 
4.2.1 Animals 
Albino Wistar rats were kept in the Laboratory Animal Service Centre, Chinese 
University of Hong Kong. Three to four rats were kept in a wire-bottomed cage, in a 
room with 12-hour light-dark cycle。Food pellet and tap water were constantly 
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available to the rats. Bedding under the cage was changed at least twice a week. 
To induce diabetes，70mg/kg STZ was intraperitoneally injected to Wistar rats 
five days after birth. STZ was dissolved in citrate buffer (0.028M citric acid 
monohydrate 0.255M citric acid trisodium salt dihydrate, pH 4.5) at 20mg/ml, and 
freshly prepared just before use. The induction of STZ-diabetes was confirmed by 
the determination of fasting hyperglycaemia at 11. I m M or over in the adult rats. 
4.2.2 Testing Method 
Experimental Procedures 
The experiment lasted for eight consecutive days (day 1 to day 8)。Treatment 
was given once per day (at the same time of each day), and plasma glucose level was 
determined on day 1 for the acute effect of the herb，and also determined on day 8 for 
the chronic effect after eight days of treatment。 
•“ t 
Rats were randomized into various groups (n > 6): negative control group (water, 
5ml/kg body weight), positive control group (metformin, 200mg/kg), and herbal 
extract treatment groups (388mg/kg Cortex Moutan or 400mg/kg Rhizoma Alismatis 
aqueous extract)。The dosages were calculated based on the human equivalent doses. 
On day 1, 10 to 12-week old n5-STZ rats were two-hour fasted, and the body 
weights were recorded. After taking the first blood sampling, rats were immediately 
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force-fed with water, metformin or herbal extracts according to their assigned groups. 
Blood samples were then collected at 45, 90, 135, 180，240 and 360 minutes after 
treatment. Rats were kept unfed until last blood sampling was taken。 
Force-fed treatments were given to rats on day 2 to day 7 without taking blood 
sample. On day 8, the experimental procedure was repeated same as day 1。 
Analysis of Plasma Glucose 
Around 0.3ml blood sample was collected from tail tip in centrifuge tube 
precoated with 5}il of 1250U/ml heparin. Blood sample was then rapidly centrifuged 
at 4000xg for five minutes for separation of plasma from blood cells. The glucose 
concentration in supernatant (plasma) was measured by glucose oxidase method. One 
milli l itre glucose assay solution was pre-warmed at 37。C. Then, plasma sample 
was added and the absorbance at 500nm was measured after five minutes incubation 
-1 
at 37。C. The absorbance was converted to actual glucose level by calibration with 
5.6mM glucose standard. 
Statistical Analysis 
Multi-level models were used to compare the rate of change of glucose level at 
each time point (t = 45, 90, 135, 180, 240, 360 min) relative to baseline (t 二 0 min) 
Chapter 4 In vivo Studies on Selected Herbs \ 111 
between each treatment group and water control group on day 1 and day 8 
respectively. The public domain software MIXREG (University of Illinois at Chicago, 
Chicago, IL, USA) was used for fitt ing multi-level models. A l l statistical tests were 
two-sided, with a significant level of 0。05. 
4.2.3 Results 
Experimental results were shown in Fig. 4.2. As the positive control, fasting 
plasma glucose level of metformin group was significantly lower than that of the 
water group on both day 1 and day 8。These results validated the experimental model. 
On both day 1 and day 8, no significant difference from water group was found 
in Cortex Moutan or Rhizoma Alismatis treatment groups. Therefore, it was 
concluded that the tested herbs did not have hypoglycaemic effect on the basal 
glycaemia in vivo. 
- 1 
After eight days of treatment, body weights of rats in all groups increased 
gradually, and no significant difference was found between treatment groups and 
water group (data not shown). No obvious side effect was observed with treatment 
groups. 
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Fig. 4.2 Basal Glycaemia Test wi th Cortex Moutan and Rhizoma Alismatis 
(a) Day 1 experiment and (b) Day 8 experiment. Results expressed as mean 士 SEM， 
n = 6. Treatments were given immediately after taking first blood sample (0 min). 
Metformin (200mg/kg) showed significant hypoglycaemic effect on both days. No 
significant effect was found in herbal treatment groups. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
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4.3 Oral Glucose Tolerance Test 
Since improving oral glucose tolerance is another possible mechanism for 
treating diabetes, OGTT was performed to study the effect of herbal aqueous extracts 
on oral glucose tolerance, using nO-STZ rats that have moderate diabetic condition 
with impaired glucose tolerance. 
4.3.1 Animals 
Wistar rats were kept as described in Section 4.2. L To induce diabetes, 
lOOmg/kg STZ was intraperitoneally injected to Wistar rats on the day of birth. STZ 
was dissolved in citrate buffer (pH 4.5) at 20mg/ml, and freshly prepared just before 
use. The induction of STZ-diabetes was confirmed by the determination of fasting 
hyperglycaemia at 7.8mM or over in the adult rats. 
- i 
4.3.2 Testing Method 
The experiment lasted for 8 consecutive days (day 1 to day 8). Treatment was 
given once per day (at the same time of each day), and OGTT was performed on day 
1 for the acute effect of the herb, and also performed on day 8 for the chronic effect 
after eight days of treatment. 
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Rats were randomized into various groups (n > 6): negative control group (water, 
5ml/kg), positive control group (metformin, 200mg/kg), and herbal extract treatment 
groups (388mg/kg Cortex Moutan or 400mg/kg Rhizoma Alismatis aqueous extract)。 
On day 1, 10 to 12-week old nO-STZ rats were two-hour fasted, and the body weights 
were recorded. After taking the first blood sampling, rats were immediately force-fed 
wi th water, metformin or herbal extracts according to their assigned groups. Second 
blood sample was taken 15 minutes after the treatment, and 2g/kg glucose was 
force-fed at 30 minutes after the drug treatment。Blood samples were then collected 
15, 30, 45，60 and 90 minutes after glucose challenge. Rats were kept unfed until last 
blood sampling was taken. 
Force-fed treatments were given to rats on day 2 to day 7 without taking blood 
sample.〇n day 8，the experimental procedure was repeated same as day 1, The 
method of determining plasma glucose and statistical analysis were the same as 
-1 
described in Section 4.2.2. 
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4.3.3 Results 
Experimental results of OGTT were shown in Fig. 4.3 and 4.4. As the positive 
control, plasma glucose level after glucose challenge of metformin group was 
significantly lower than that of the water group on both day 1 and day 8. These 
results validated the experimental model. 
On both days 1 and 8, no significant difference from water group was found in 
either Cortex Moutan or Rhizoma Alismatis treatment groups。Therefore, it was 
concluded that the tested herbs did not improve oral glucose tolerance in vivo. Again, 
no difference in body weights or obvious side effect were observed among treatment 
groups and control groups (data not shown). 
t '' 
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Fig. 4.3 Oral Glucose Tolerance Test wi th Cortex Moutan 
(a) Day 1 experiment and (b) Day 8 experiments. Results expressed as mean 士 SEM, 
n = 18 to 22. Treatments were given immediately after taking first blood sample (-30 
min), and glucose challenge was given at 0 min. Metformin but not Cortex Moutan 
treatment showed significant anti-hyperglycaemic effect. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < O W L 
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Fig. 4.4 Oral Glucose Tolerance Test with Rhizoma Alismatis 
(a) Day 1 experiment and (b) Day 8 experiment. Results expressed as mean 士 SEM, 
n = 18 to 22. Treatments were given immediately after taking first blood sample (-30 
min)，and glucose challenge was given at 0 min. Metformin but not Rhizoma 
Alismatis treatment showed significant anti-hyperglycaemic effect. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
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4.4 Discussion 
Neonatal-STZ models are well-characterized for type 2 diabetic studies 
(Schaffer and Mozaffari, 1999). It has been validated by certain classes of oral 
anti-diabetic agents with different modes of action, including sulphonylureas and 
a-glucosidase inhibitors (Degirmenci et al., 2002; Portha and Serradas, 1991). Our 
studies also showed that metformin, the commonly used anti-diabetic drug, 
significantly lowered the basal glycaemia and improved oral glucose tolerance in 
neonatal-STZ rats。Therefore, this model is suitable for investigating the effect of 
potential anti-diabetic agents. 
In our studies, both nO-STZ and n5-STZ were used. The characteristic 
differences between these two models were listed in Table 4A. Comparing with 
nO-STZ, n5-STZ is more severely diabetic, with much higher basal glycaemia level, 
lower basal insulin level, and decreased pancreatic P-cells number and insulin 
- 1 
content. Both models are glucose intolerance, however, insulin resistance is only 
observed in n5-STZ (Blondel et al., 1989; Wang et al, 1996). 
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Table 4.1 Characteristics of nO-STZ and n5-STZ Diabetic Rats 
nO-STZ n5-STZ 
Hyperglycaemia M i ld Severe 
Glucose intolerance Yes Yes 
Number of p-cells 40% of normal 20% of normal 
Basal plasma insulin Nearly normal 50% of normal 
Pancreatic insulin content 50% of normal 10% of normal 
Insulin resistance No Yes 
(Blondel et al., 1989; Wang et al., 1996) ” 
Chapter 4 In vivo Studies on Selected Herbs \ 120 
In basal glycaemia test, since the aim was to observe the lowering effect on basal 
plasma glucose, an initial high plasma glucose level would allow more obvious 
hypoglycaemic effect to be observed. Therefore, n5-STZ rats were used. In addition, 
n5-STZ exhibited insulin resistance, which allowed investigation on the potential 
drug effect on improving insulin sensitivity. On the other hand, in OGTT, nO-STZ 
model was used instead as unlike n5-STZ, it had impaired oral glucose tolerance, 
wi th more similar glycaemic level to human type 2 diabetes。 
Among the two tested herbs, Cortex Moutan (388mg/kg) and Rhizoma Alismatis 
(400mg/kg) aqueous extracts did not give any positive effects in both basal 
glycaemia test and OGTT. In fact, a range of lower doses on both herbs were tested 
preliminarily, but no positive result was found either (data not shown). Since the 
reported dosages were already very high in human use (equivalent dose estimated to 
be lOg/day aqueous extract of single herb), it was unrealistic to further increase the 
"J 
dosages. It is also important to note that from our preliminary results, F2 did not have 
any effect on basal plasma glucose or improving oral glucose tolerance (data not 
shown). Hence，it was not too surprising to see the negative results of the two herbs. 
The amounts of sugars in the two herbal extracts were calculated using the 
percentages in Table 2.6. For example, Cortex Moutan extract contained 7.79% w/w 
of glucose, therefore the amount of glucose ingested after taking 388mg/kg of Cortex 
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Moutan extract was 388mg/kg x 7.79% = 30.23mg/kg. Results were shown in Table 
4.2.. 
When comparing with the glucose challenge used in OGTT (2000mg/kg), the 
amount of glucose from Cortex Moutan and Rhizoma Alismatis was only accounting 
for 1.22% and 0.59% respectively, and hence should not have any significant 
interference with the results. When considering the total amount of three sugars, the 
sugar dosages ingested after Cortex Moutan treatment was 7.40% of the glucose 
challenge in OGTT. However, this amount of sugar should still be insufficient to give 
false negative result. 
In contrast to the promising results obtained in various in vitro studies, it was 
found that Cortex Moutan and Rhizoma Alismatis aqueous extracts did not exhibit 
any acute or chronic anti-diabetic effects in vivo. The conflicting results obtained 
from in vitro and in vivo studies might be due to several possible reasons, such as 
-1 
breakdown of active components during digestion, or the active components not 
being absorbed. It might also be due to the difficulty of correlating the dosages in in 
vitro and in vivo studies, since the absorption rate of different compounds in crude 
extracts would largely vary. Variation between individual rats would also decrease 
the power of statistical analysis, requiring a larger sample size to detect the effects of 
herbal medicines i f they were not as potent as anti-diabetic agents like metformin. 
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Table 4.2 Dosages of Sugars Ingested after Taking Herbal Extracts 
Sugar dosages (mg/kg) 
Herbal extracts Drug dosages Glucose Fructose Sucrose Total 
Cortex Moutan 388mg/kg 30.23 24.37 93.47 148.06 
Rhizoma Alismatis 400mg/kg 8.20 1L80 16.12 36.12 
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The neonatal-STZ model also has its limitations. Since diabetes is induced 
chemically by destroying P-cells, the neonatal-STZ rats have hypoinsulinaemia 
instead of hyperinsulinaemia. The neonatal-STZ rats are not obese; their body 
weights are in fact lower than normal rats. Also, insulin resistance is not found in 
nO-STZ rats. Therefore, the neonatal-STZ model is not f l i l ly representing human type 
2 diabetes and such limitations could affect the drug studies. Hence, for further 
studies, genetic type 2 diabetic animal models, such as db/db mice, Zucker fatty rats 
and Goto-Kakisaki rats, should be used in order to confirm our results. 
Although the results of in vivo studies were disappointing, it should be noted that 
the CHCI3 extract from Cortex Moutan aqueous extract showed very potent effects 
on inhibiting intestinal glucose absorption in vitro (Fig 3.2)。Therefore, it was 
hypothesized that the active component(s) of Cortex Moutan might be of non-polar 
properties. Hence it is interesting to extract the active component(s) from Cortex 
Moutan. In the next chapter, bioassay-guided fractionation of Cortex Moutan using 
B B M V as the in vitro bioassay wi l l be discussed. 
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Chapter 5 
Bioassay-guided Fractionation of 
Cortex Moutan 
5.1 Introduction 
With the potent in vitro inhibition of glucose uptake in BBMV, bioassay-guided 
fractionation of Cortex Moutan was carried out in order to find the active 
constituent(s). 
5.1.1 Phytochemical Studies of Cortex Moutan 
As a commonly used herb in TCM, the phytochemistry of Cortex Moutan has 
been extensively studied. Apart from those trivial compounds such as simple sugars 
and amino acids, its major components can be mainly divided into four groups: 
‘ < 
Acetophenones: Paeonol (Fig. 5.1a(i)) is a phenolic acetophenone found in 
Cortex Moutan. Together with minor acetophenones, they exhibited potent 
antibacterial, anti-inflammatory and anticoagulation activities (Lin and Chem, 1991). 
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Fig. 5.1 Structures of Compounds Found in Cortex Moutan 
(a) i. Paeonol: R = H; ii. Paeonoside: R = P-D-glucopyranosyl; 
(b) i. Paeonisuffrone: R = OH; ii. Deoxypaeonisuffrone: R = H; 
(c) Paeonisuffral; (d) Mudanpinoic acid A 
(e) i. Paeonolide: R1 = R2 - R3 = H; 
ii. Suffmticoside C: R1 = R2 = H, R3 = galloyl 
ii i. Suffmticoside D: R1 二 R3 二 H, R2 = galloyl; 
iv. Suffmticoside E: R1 二 (3-D-glucopyranosyl, R2 = R3 = H; 
(f) i. Paeoniflorin: R = H; ii. Oxypaeoniflorin: R = OH; 
(g) 1,2,3,4,6-Penta-O-galloyl-P-D-glucose: R = galloyl 
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Terpenoids: Most terpenoids found in Cortex Moutan are monoterpenes, 
including paeonisuffrone (Fig. 5.1b(i)), deoxypaeonisuffrone (Fig。5.1b(ii)), 
paeonisuffral (Fig. 5.1c), isopaeonisuffral and paeonisothujone (Yoshikawa et al., 
1994，2000). Atriterpenoid, mudanpinoic acid A (Fig. 5.Id) was also found in Cortex 
Moutan (Lin et al, 1998). 
Glycosides: Several paeonol glycosides are found in Cortex Moutan, 
including paeonoside (Fig. 5.1a(ii)), apiopaeonoside, paeonolide (Fig. 5.1e(i)), and 
different suffruticosides (Fig. 5。le(ii, i i i , iv)) (Matsuda et al” 2001)。There are also 
monoterpene glycosides, including paeoniflorin (Fig. 5.1f(i)), oxypaeoniflorin (Fig. 
5.1f(ii)), and their benzoyl or galloyl derivatives, and many mudanpiosides (Ding et 
al, 1999; Matsuda et al” 2001; Yoshikawa et al., 2000). 
-i 
Tannins: There are many galloyl-glucose found in Cortex Moutan (Wu et aL, 
2003a). One of the well-known compound is 1,2,3,4,6-penta-O-galloyl-P-D-glucose 
(Fig. 5.1g), due to its possible anti-cancer effect (Ho et al., 2002; Oh et al, 2001). 
Among these known compounds, only paeoniflorin was reported for its 
anti-diabetic effect, by reducing basal glycaemia and improving glucose tolerance of 
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STZ-treated rats (Hsu et al., 1997). A polysaccharide isolated from Cortex Moutan 
with unknown structure was also reported for in vivo anti-diabetic activity (Hong et 
a/., 2003). 
5-2 Organic Extraction of Cortex Moutan 
In the previously described B B M V glucose uptake assays, the chloroform 
soluble fraction of herbal aqueous extract was used for exclusion of glucose from the 
herbs. However, the yield of such extraction was very low。In order to obtain more 
water-insoluble components for further phytochemical studies, the extraction 
procedure was changed by using organic solvent to extract the herb directly。 
5.2.1 Extraction Method 
One kilogram of raw material of Cortex Moutan was cut into small pieces and 
-1 
covered with 2L 95% EtOH (EtOH-I^O, 95:5, v/v; Uni-Chem, South Kearny, NJ， 
USA). After refluxing for two hours, the extract solution was collected and fresh 
950/0 EtOH was added for another two-hour extraction. Solutions of two extractions 
were combined. Solvent was evaporated using rotary evaporator to obtain the 
ethanolic extract of Cortex Moutan (CM-A). 
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CM-A was re-dissolved in 500ml distilled water and partitioned with 500ml 
hexane (Lab-Scan, Bangkok, Thailand). Hexane fraction was collected, and the water 
fraction was partitioned again with 500ml of fresh hexane. The remaining water 
fraction (CM-B) was discarded. Two hexane fractions were combined. Anhydrous 
sodium sulphate (MERCK, Darmstadt, Germany) was added to absorb remaining 
moisture in hexane extract. The mixture was filtered and the hexane extract (CM-C) 
was dried using rotary evaporator. 
5.2.2 Results 
The Cortex Moutan raw material was extracted by 95% EtOH, giving the 
ethanolic extract of Cortex Moutan (CM-A), with extraction yield of 10.16% w/w. 
CM-A was partitioned between water and hexane. The extraction yields of the 
hexane fraction (CM-C) from the raw material and CM-A were 1.96% w/w and 
-1 
19.34% w/w respectively. CM-C was a pale brown solid, with characteristic odour of 
raw Cortex Moutan. A simplified extraction procedure was shown in Fig. 5.2. 
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Cortex Moutan Raw Material (lOOOg) 
95% EtOH extraction 
1 r 




Water Fraction Hexane Fraction 
(CM-B, discarded) (CM-C, 19.64g) 
Fig. 5.2 Organic Extraction Procedure of Cortex Moutan 
-1 
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5.3 BBMV Glucose Uptake Assay with Fraction CM_C 
Due to the change in extraction method, the effect of CM-C on B B M V glucose 
uptake was tested before any further studies。 
5.3.1 Materials and Methods 
The materials and methods were the same as described (Section 3.2.2.5). Since 
CM-C was insoluble in water, it was re-dissolved in 100% EtOH (MERCK, 
Darmstadt, Germany), and diluted by water to become 4% v/v EtOH, which the final 
concentration would become 2% in the reaction mixture. The results of CM-C 
treatment were compared against 2% v/v EtOH treatment (as control). Water control 
was performed to monitor the effect of 2% v/v EtOH on glucose uptake o f B B M V . 
5.3.2 Results 
-1 
The results of B B M V glucose uptake with CM-C were shown in Fig. 5.3. No 
significant difference was found between 2% v/v EtOH group and water control 
group. Therefore, it validated that using of 2% v/v EtOH would not affect the 
glucose uptake of BBMV. In all tested dosages, CM-C significantly inhibited the 
glucose absorption of BBMV, in a dose-dependent manner. At Img/ml, over 90% 
inhibition was observed. 
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Fig. 5.3 Glucose Uptake of B B M V with CM-C Treatment 
Results expressed as mean 士 SEM, n = 7 to 9. 
-i 
Significantly different from 2% v/v EtOH: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
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5.4 In vivo Studies of Fraction CM-C 
With the promising effect in B B M V studies, the in vivo anti-diabetic effect of 
CM-C was tested using neonatal-STZ rats。Both basal glycaemia test and OGTT 
were performed. 
5.4.1 Materials and Methods 
The methods of performing basal glycaemia test and OGTT were the same as 
described in Chapter 4。CM-C was grinded into fine powder, and force-fed as 
suspension in water. The dosage of CM-C used for testing was 200mg/kg, same as 
the positive control metformin to allow direct comparison. 
5.4.2 Results 
Results of basal glycaemia test with CM-C were shown in Fig. 5.4. On both days 
-1 
1 and 8, metformin showed significant effect to lower the fasting glycaemia and 
hence the tests were validated. However, CM-C group did not show any significant 
difference from the water control group. Therefore, it was concluded that the CM-C 
did not have hypoglycaemic effect in vivo. 
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Fig. 5.4 Basal Glycaemia Test wi th Fraction C M C 
(a) Day 1 experiment and (b) Day 8 experiment. Results expressed as mean 士 SEM, 
n = 6. Treatments were given immediately after taking first blood sample (0 min). 
Metformin (200mg/kg) showed significant hypoglycaemic effect on both days. No 
significant effect was found in 200mg/kg CM-C group. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < 0.001 
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Results of OGTT wi th CM-C were shown in Fig. 5.5. On both days 1 and 8, 
metformin showed significant effect to improve oral glucose tolerance and hence the 
tests were validated. In OGTT, CM-C significantly improved oral glucose tolerance 
on both day 1 and day 8. On day 1, significant effect was observed at 30 min after 
glucose load by CM-C treatment, which was 12.9% lower than that o f water group. 
A t the same time point，metformin provided a 24.6% decrease in plasma glucose。 
After eight days of treatment, CM-C showed significant anti-hyperglycaemic effect 
at 30, 45 and 60 min after oral glucose challenge, wi th 13.8%, 12.9% and 15.1% 
decrease in plasma glucose level as compared with water control group respectively. 
For metformin, 26,1%, 29.4% and 27.5% decreases were observed respectively for 
these time points. 
To summarize, the anti-hyperglycaemic effect of CM-C was similar with single 
dose treatment or chronic treatment, and no obvious chronic accumulative effect was 
observed. The higher significant level on day 8 was due to lower variation among 
individual rats. With tested dosages at 200mg/kg for both metformin and CM-C, the 
anti-hyperglycaemic activity of CM-C was only about half of that of metformin. 
After eight days of treatment, body weights of rats in all groups increased 
gradually, and no significant difference was found between CM-C group and water 
group (data not shown). No obvious side effect was observed with CM-C treatment. 
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Fig. 5.5 Oral Glucose Tolerance Test with Fraction C M C 
(a) Day 1 experiment and (b) Day 8 experiment. Results expressed as mean 士 SEM, 
n = 18 to 22. Metformin (200mg/kg) and CM-C (200mg/kg) showed significant 
anti-hyperglycaemic effects on both days. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
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5.5 Fractionation of Fraction CM-C 
With the promising in vitro and in vivo effects, CM-C was fractionated using 
silica-gel column-chromatography. The fractionation was guided by B B M V glucose 
uptake assay. Using column-chromatography allowed separation of compounds in 
large scale, providing adequate amount of samples for the bioassay and structure 
elucidation. 
5.5.1 Materials and Methods 
Materials 
Silica-gel 60, anisaldehyde, glacial acetic acid, and silica-gel 60 F254 pre-coated 
TLC plate were purchased from MERCK (Darmstadt, Germany). Paeonol and 
paeoniflorin reference compounds were purchased from National Institute for the 
Control of Pharmaceutical and Biological Products (Beijing, China). MeOH, hexane 
-1 
and EtOAc were purchased from Lab-Scan (Bangkok, Thailand). Concentrated 
sulphuric acid were purchased from BDH Laboratory Supplies (Poole, UK). 
Sample preparation 
Fraction CM-C (5.805g) was completely dissolved in MeOH, and mixed with 
lOg silica-gel 60. Solvent was completely dried by rotary-evaporator to obtain a 
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mixture of CM-C and silica gel in powder form. 
Column chromatography 
Three hundred grams of silica-gel 60 was mixed with the eluent (hexane-EtOAC, 
7:3, v/v). The mixture was loaded in a glass column and until the silica gel was 
tightly packed inside the column. The length of column was 240mm and diameter 
was 51mm. CM-C/silica gel mixture was gently placed on top of the column。The 
column was then eluted with the eluent under gravity. Fractions were collected 
manually according to the appearance of compounds. The chemical profiles of 
fractions were analyzed by TLC. Fractions with the same chemical profile were 
combined. Finally the column was flushed with 100% EtOAc in order to elute all the 
remaining substances inside the column。Fractions were completely dried with rotary 
evaporator and weighed. 
T L C analysis 
The procedure for TLC analysis was the same as described in Section 2.3.2.2. 
Samples were separated using Silica-gel 60 F254 pre-coated TLC plate, with 
hexane-EtOAC (7:3, v/v) as mobile phase。Paeonol (Fig. 5.1a(i)) and paeoniflorin 
(Fig. 5.1f(i)), which were commercially available reference compounds of Cortex 
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Moutan, were also applied. For detection, plate was visualized under 254nm and 
365nm U V light, and also sprayed with anisaldehyde-sulphuric acid reagent (a 
mixture of 0.5ml anisaldehyde, 10ml glacial acetic acid, 85ml methanol, 5ml 
concentrated sulphuric acid, freshly prepared) and heated at 100。C for five minutes. 
5.5.2 Results 
The CM-C was fractionated using silica-gel column chromatography. A total of 
160 fractions were obtained, and combined into final 15 fractions according to their 
chemical profiles, known as CM-C l to CM-C 15. The weights of these fractions were 
shown in Fig. 5.6. Generally, weights of most fractions were less than lOOmg. 
However, weights of CM-C3 and CM-C4 were very high, with 785.2mg and 
3570.6mg respectively. A reasonable total yield of 88.25% was obtained, indicating 
that most of the components had been collected and the amount of substance left 
-1 
inside the column was small。 
The TLC chromatogram of the final 15 fractions was shown in Fig. 5.7. For the 
two reference compounds, paeoniflorin did not move up the plate but stayed on the 
baseline, while paeonol had an Rf value of 0.75. For the 15 fractions, an obvious 
polarity gradient was observed. 
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Fractions Weight (mg) 
• CM-Cl 52.8 
• CM-C2 7.7 
• CM-C3 785.2 
• CM-C4 3570.6 
• CM-C5 40.0 
• CM-C6 1.4 
• CM-C7 142.9 
C M C Silica-gel Column 
‘ • CM-C8 16.0 
(5.805g) 
• CM-C9 52.9 
— • CM-C 10 56.5 
• CM-C 11 29.5 
• CM-C 12 43.5 
• CM-C 13 18.3 
- i 
• CM-C14 24.0 
- • CM-C 15 281.8 
Total weight 5123.1 
Yield 88.25% 
Fig. 5.6 Fractionation of CM-C 
CM-Cl to CM-C 14: Eluted with Hexane-EtOAc (7:3，v/v); 
CM-C 15: Flushed with 100% EtOAc 


































































































































































































































































5.6 BBMV Glucose Uptake Assay with CM-C Sub-fractions 
In order to investigate the in vitro glucose absorption inhibitory effects of the 
CM-C sub-fractions, B B M V glucose uptake assays were performed, same as 
described in Section 5.3.1. Paeonol and paeoniflorin were also tested. 
5.6.1 Results 
B B M V glucose uptake assay was performed with the CM-C sub-fractions and 
results were shown in Fig. 5.8a. The CM-C showed very potent inhibitory effect, and 
two ranges of its sub-fractions significantly inhibited B B M V glucose uptake, 
including CM-C2 to CM-C5 (Range A) and CM-C 10 to CM-C14 (Range B). For 
those two tested reference compounds, paeonol significantly inhibited the glucose 
uptake, while paeoniflorin showed stimulatory effect. For those fractions showed 
inhibitory effect more than 25%, their dose-dependent effects were further 
"< 
investigated using three concentrations, from 0.25mg/ml to l.Omg/ml. From their 
results (Fig. 5.8b), dose-dependent inhibitory effects were observed in all tested 
fractions, as well as paeonol. 
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Fig. 5.8 B B M V Glucose Uptake Assay with CM-C Sub-fractions 
(a) A l l fractions tested at 1 mg/ml; (b) Fractions tested with different concentrations. 
Results expressed as mean 士 SEM, n 二 8. 
Significantly different from 2% v/v EtOH: * p < 0.05, * * p < 0.01，*** p < O.OOL 
Keys: W - Water blank; E - 2% v/v EtOH; CMC - Fraction CM-C; 
PAE - Paeonol; PAF - Paeoniflorin; 
1 to 15 - Fractions CM-Cl to CM-C 15. 
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The B B M V results were compared with the TLC chromatogram (Fig. 5.7). It 
was found that pale yellow spots with Rf values around 0.75 were shared by the 
Range A fractions, and red spots with Rf values around 0.67 were shared by the 
Range B fractions, which suggested that the active ingredients might be presence in 
these spots. Since the chemical profiles of Range A and Range B fractions were very 
different, there should be at least two active compounds exist in CM-C, In addition, 
the pale yellow spots in Range A showed the same Rf value and U V 254nm 
absorption with the paeonol reference. Therefore, it was suspected that the active 
component in Range A fractions was paeonol 
5.7 Isolation of Active Compound in Fraction CM-C4 
Since it was suspected that the active compound in Range A fractions was 
paeonol, the compound was isolated for structure elucidative studies. Since CM-C4 
was the heaviest among the fractions in Range A, the suspected compound was 
purified from this fraction, using preparative TLC. The advantage of preparative 
TLC is providing rapid separation with high resolution. In a pilot study, TLC 
analysis using hexane-EtOAc (9:1, v/v) as the mobile system separated CM-C4 into 
three spots. The spot showed the same Rf value (0.44) of paeonol was isolated by 
preparative TLC. 
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5,7.1 Materials and Methods 
Fraction CM-C4 (15.0mg) was dissolved in MeOH and the solvent was 
completely applied as a long band on the baseline of a silica-gel 60 F254 pre-coated 
0.5mm TLC plate (20cmx20cm; MERCK, Darmstadt, Germany). The plate was 
developed using hexane-EtOAc (9:1, v/v; Lab-Scan, Bangkok, Thailand) as the 
mobile phase. The developed plate was visualized under U V at 254nm. The band 
with Rf value around 0.44 which quenched U V was scrapped off, and ultrasonicated 
with EtOAc for 30 minutes. The mixture was filtered to remove silica-gel, and the 
solution was completely dried using rotary-evaporator. Weight of residue (CM-C4a) 
was recorded. 
The purity of CM-C4a was checked using TLC analysis, with hexane-EtoAc (9:1, 
v/v) as the mobile phase. Other conditions were the same as described in Section 
5.5.1. 
-» 
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5.7.2 Results 
Preparative TLC was performed, and the purity of the isolated compound 
(known as CM-C4a) was checked by TLC (Fig 5.9). Three spots were detected in 
fraction CM-C4. The one with Rf value of 0.44 was scraped off from the preparative 
TLC plate to obtain the CM-C4a. After purification, only one spot was detected in 
the TLC chromatogram of CM-C4a. From 15.0mg CM-C4, l l .Smg CM-C4a was 
purified, with the yield of 78.7% w/w. CM-C4 was pink crystal, and CM-C4a was a 
white powder, which was same as paeonol reference. 
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0.44 0.44 0.44 
0.24 
0.18 
PAE C4 C4a 
Fig. 5.9 Preparative T L C Purif ication of Fraction CM-C4 
Stationary Phase: Silica-gel 60 F254 
Mobile Phase: Hexane-EtOAc (9:1) 
Detection: Anisaldehyde-sulphuric acid reagent, 100°C for 5 minutes, visible light 
Keys: PAE - Paeonol reference compound; 
C4 - Fraction CM-C4 
C4a — Isolated compound 
Numbers shown on the photo are Rf values of spots 
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5.8 Structure Elucidation of CM-C4a 
Structure of CM-C4a was elucidated by mass spectrometry (MS) and proton 
nuclear magnetic resonance (^H-NMR), and compared with paeonol reference 
compound and previous reports. MS studies provided information on the molecular 
weight of the studied compound, and also of the fragments generated during electron 
impact (EI). On the other hand, ^H-NMR provided information on the assignment of 
hydrogen atoms in the studied molecule。 
5.8.1 Materials and Methods 
Mass Spectrometry 
MS analysis was performed using Thermo (Bremen, Germany) M A T 95XL Gas 
Chromatographic Mass Spectrometer. Both of low resolution and high resolution EI 
spectra were obtained for both reference compound paeonol and isolated compound 
-1 
CM-C4a，for the analysis of compound fragments and determining the molecular 
weights of the compounds. 
IH-NMR Analysis 
'H-NMR analysis was performed using Bruker (Rheinstetten, Germany) Avance 
DPX300 NMR Spectrometer。Paeonol (8.2mg) and CM-C4a (7.2mg) were 
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individually dissolved in 0。75ml of deuterium chloroform (CDCI3； Aldrich, St. Louis, 
MO, USA). Their 300MHz ^H-NMR spectra were detected. Chemical shifts were 
detected relative to reference tetramethylsilane. 
5.8.2 Results 
Summary of the results of MS studies were listed in Table 5.1. For both paeonol 
reference and CM-C4a, the low resolution EI mass spectra (Appendices 1 and 2) 
showed the molecular ion peak at m/z 166. The molecular formula C9H10O3 
(molecular weight: 166.0624) was confirmed by high resolution EI mass spectra 
(Appendices 3 and 4)。The spectra were matched with literature report for paeonol 
(Weeks et al, 1977)。 
The proton assignments of paeonol and CM-C4a were detected by ^H-NMR and 
summarized in Table 5.2 and Fig 5.10. The CM-C4a showed the same proton 
assignment to the paeonol reference, except that the coupling constants of H-3 were 
different, which might due to the inadequate resolution of the spectra, as chemical 
shift values were only given to two decimal places (Appendices 5 and 6). Both 
spectra also matched with literature report (Zhou et al,, 1981). Therefore, it was 
concluded that CM-C4a was paeonol. 
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Table 5.1 Peak Assignment of Mass Spectra of Paeonol Reference and CM-C4a 
Relative abundance (%) 
Paeonol reference Literature data 
Peak (m/z) CM-C4a 
compound (Weeks et al； 1977) 
= ‘ ‘ ； '| ‘ I • ：'；' ‘ '• .••_-••• • I ‘ '•‘ •••I- •• ‘ I . • .. ‘ — .-j.-j, '„ I'.T- „• . ^ ― • • , L • = 
166, M+ 40 38 42 
151 100 100 100 
108 7 7 8 
95 8 9 7 
44 45 28 — 
43 7 4 8 
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Table 5.2 Proton Assignments of Paeonol Reference and CM-C4a 
Chemical shift (6 ppm) 
Paeonol reference Literature data 
Protons CM-C4a 
compound (Zhou et al., 1981) 
3H, s, COCH3 2.56 2.56 2.55 
3H, s, OCH3 3.84 3.84 3.82 
2H, m, H-4, 6 6.42 to 6.46 6.42 to 6.46 6.38 to 6.39 
IH, d, H-3 7 .63,J=6Hz 7.63, J = 9 H z 7.60, J - 9 H z 
IH, s, OH 12.75 12.75 12.67 
Abbreviations: s - Singlet; d - Doublet; m - Multiplet; J -Coupl ing constant. 
s, 5 二 2。56 — K 厂 s, 5 = 12.75 
H o C . / O / 
d, 3 二 7.63 3 I 
H y A ^ O H 
-i 
/ H Y H 
m, 5 = 6.42-6.46 , O \ 
/ H 3 C \ 
Z L m, 3 = 6.42-6.46 
s, 6 = 3.84 ^ 
Fig. 5.10 Proton Assignment of Paeonol 
Proton assignment of paeonol standard was detected by 300MHz ^H-NMR. 
Chemical shift values were shown in ppm. 
Abbreviations: s - Singlet; d - Doublet; m - Multiplet. 
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5.9 Effect of Paeonol in Oral Glucose Tolerance Test 
Since it was confirmed that part of the in vitro inhibitory effect on intestinal 
glucose absorption was due to paeonol, the in vivo anti-diabetic activity of paeonol 
was further studied using OGTT. Basal glycaemia test was not performed because no 
significant effect was found in the fraction CM-C, and inhibition of intestinal glucose 
absorption is directly related to improving oral glucose tolerance. 
Since paeonol was only sparingly soluble in water, y-cyclodextrin was added to 
promote the formation of a suspension. y-Cyclodextrin is a ring-shaped molecule 
made up of eight glucose units. Its annular structure forms a hydrophobic cavity that 
allows incorporation of organic molecules, while the hydrophilic outer surface makes 
it water-soluble. It is currently being used as a food additive and the toxicity is 
considered to be very low (Joint FAO/WHO Expert Committee on Food Additives, 
2000). 
5.9.1 Materials and Methods 
The methods of performing OGTT were the same as described in Chapter 4. 
Rats were assigned to four different groups: negative control group (5ml/kg water), 
positive control group (200mg/kg metformin in water), solvent control group 
(84mg/kg y-cyclodextrin (L68% w/v; Wako, Osaka, Japan) in water), low dose 
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paeonol group (200mg/kg paeonol (Aldrich, St. Louis, MO, USA) in 1.68% w/v 
y-cyclodextrin) and high dose paeonol group (400mg/kg paeonol in 1.68% w/v 
y-cyclodextrin). High dose paeonol (400mg/kg) was only tested on day 1 for this 
preliminary study due to insufficient of paeonol. 
Multi-level models were used to compare the rate of change of glucose level as 
previously described, between water group and metformin group, water group and 
solvent control group, and each of paeonol groups and solvent control group, 
respectively. 
5.9.2 Results 
Oral glucose tolerance test with paeonol was performed once only due to time 
limitation. Preliminary results were shown in Fig. 5.11. On both days 1 and 8, 
metformin showed significant anti-hyperglycaemic effect comparing with water 
"4 
group and thus the tests were validated. The solvent control group (84mg/kg 
y-cyclodextrin) did not show any significant difference to water group on both days, 
suggesting that y-cyclodextrin itself did not have any significant effect on plasma 
glucose. 
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Fig. 5.11 Oral Glucose Tolerance Test wi th Paeonol 
(a) Day 1 experiment and (b) Day 8 experiment. Results expressed as mean 士 SEM, 
n 二 6 to 9. Metformin (200mg/kg) showed significant anti-hyperglycaemic effect on 
both days. y-Cyclodextrin (84mg/kg) did not show any significant difference from 
water control. Paeonol (200 and 400mg/kg) showed a trend of anti-hyperglycaemic 
effect on day 1, but did not reach statistical significance. Such trend almost 
diminished on day 8 for 200mg/kg paeonol. 
Significantly different from water control: * p < 0.05, * * p < 0.01, * * * p < 0.001. 
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On day 1, no significant difference was found between each paeonol group and 
solvent control group. However, a trend of anti-hyperglycaemic effect was observed 
in both paeonol groups. The largest decrease in plasma glucose was observed at 45 
min after oral glucose challenge. For 200mg/kg and 400mg/kg paeonol, maximum 
decreases in plasma glucose were 15.6% and 12.5% respectively. Therefore, no 
obvious dose-dependent effect was found among these tested doses of paeonol. 
However, after eight days of treatment, the trend of anti-hyperglycaemic effect 
exhibited by 200mg/kg paeonol was no longer obvious. At 45 min time point, the 
200mg/kg paeonol group was only 5.5% lower than that of solvent control. Therefore, 
the observed trend of anti-hyperglycaemic effect of paeonol required to be confirmed 
by further experiments. 
After eight days of treatment, body weights of rats in all groups increased 
gradually, and no significant difference was found between treatment groups and 
- i 
control groups (data not shown). No obvious side effect was observed with 
y-cyclodextrin and paeonol treatments. 
5.10 Discussion 
In the present study, paeonol (2'-hydroxy-4'-methoxyacetophenone, C 9 H 1 0 O 3 ) 
was isolated from Cortex Moutan, the dried root bark of Paeonia suffruticosa. At 
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room temperature, it is a white powder，which is soluble in organic solvents but only 
sparingly dissolved in water (Ji, 1999). The amount of paeonol in the raw herb 
material in the present study could be estimated as follows: 
From TLC analysis (Fig. 5.7), paeonol was found in fractions CM-C2 to CM-C5. 
For calculations, CM-C2 and CM-C5 were neglected as they contained many other 
compounds. The total weight of CM-C3 and CM-C4 were 785.2mg + 3570.6mg = 
4355.8mg. From the results of preparative TLC, the amount of paeonol estimated in 
CM-C4 was 78.7%. Assuming the amount of paeonol in CM-C3 was the same as 
CM-C4, total paeonol in these fractions would be 4355.8mg x 7 8 J % = 3428.0mg. 
Since paeonol was isolated from 5805mg of CM-C, the percentage weight of paeonol 
in CM-C was 3426.6mg / 5805.0mg x 100% = 59。lo/o。As 19.64g of CM-C was 
extracted from lOOOg of raw herb (Fig。52), the percentage weight of paeonol in raw 
herb was estimated to be 0.591 x 19.64g / lOOOg x 100% = 1.16% w/w. This 
" I 
estimation assumed that all paeonol in the raw herb was extracted into fraction CM-C, 
which might not be true. Besides, the amount of paeonol in CM-C2 and CM-C5 have 
not been taken into account. Therefore, the studied raw herb of Cortex Moutan 
should contain at least 1.16% w/w of paeonol 、 
Paeonol is a well-known compound in Cortex Moutan. It is used as a chemical 
marker for Cortex Moutan, and required to be not less than 1.20% w/w in completely 
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dried raw Cortex Moutan by the Chinese Pharmacopoeia (State Pharmacopoeia 
Commission, 2000). This requirement should be fulf i l led with our Cortex Moutan 
sample. However, the more accurate amount of paeonol in the raw herb should be 
determined using HPLC analysis. 
Paeonol has a broad spectrum of pharmacological actions. It exhibited 
anti-inflammatory effect through inhibiting prostanoid synthesis (Hirai et al, 1985), 
and inhibiting the cascade of proinflammatory cytokines (Chou, 2003; K im et al” 
2004b)。It also showed some aspirin-like properties, such as decreasing whole blood 
viscosity, lowering haematocrit and possessing anti-aggregation activity (L i et aL, 
2000). It was proposed that the anti-aggregatory effect was due to inhibiting the 
thromboxane synthesis (Hirai et al,, 1983). Paeonol also showed protective effect on 
blood vessels, by normalizing the serum lipid ratios (Dai et al” 1999; Shi et al,, 
1988). It had also been reported to possess anti-microbial activities against flingi and 
" J 
bacteria (L i et al., 2003; Wu et al., 2003b; Yokota et aL, 1978), anti-oxidative (Ma et 
al., 1998; Zhang et al., 1999), and analgesic properties (Chou, 2003; Liu et al, 1993). 
However, among this wide range of reported pharmacological actions, none of them 
were related to the improvement of oral glucose tolerance, which was observed in the 
present study. Paeonol also occurs in the form of glycosides, including paeonoside, 
apiopaeonoside, paeonolide and five different suffmticosides (Fig. 5.1). However, 
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these compounds have never been reported to possess anti-diabetic effect. 
Paeonol, as its name suggested, it is a component isolated from the Paeonia 
genus. In the present study, it was isolated from root bark of Paeonia suffruticosa of 
family Paeoniaceae. However, the compound had also been previously isolated from 
different plant species belonging to family Paeoniaceae, including Paeonia broteroi 
(De Pascual et al, 1979), Paeonia delavayi and Paeonia szechuanica (Yu et al., 
1985). In addition, paeonol was also found in plants other than those in Paeoniaceae 
family, such as Adenophora striata (Ueyama and Furukawa, 1987), Arisaema 
erubescens (Ducki et al., 1995), Cynanchum komarovii (Fang et al” 1989)， 
Cynanchum paniculatum (Lou et al” 1989), Exacum affine (Matsumoto, 1994), 
Folotsia sarcostemmoides (Rasoanaivo et al, 1991), Luculia intermedia (Zhou et aL, 
1981), Neonauclea sessilifolia, (Kang et aL, 2002), Primula viscosa (Goris and Canal, 
1945), Primula auricula, Pycnostelma paniculutum, Betula platyphylla, and Bathysa 
-< 
meridionalis (Ji, 1999). However, among these plants, none of them were previously 
reported for any potential anti-diabetic activities. 
The present study showed that the hexane soluble fraction of Cortex Moutan 
CM-C inhibited B B M V glucose absorption in vitro. It should be noted that among 
fraction CM-C, two ranges of sub-fractions were found active (Fig. 5.8a). As the 
TLC analysis showed that the two ranges of sub-fractions did not share any spots in 
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common (Fig. 5.7), it suggested that at least two compounds were responsible for the 
effect of CM-C. From our results, it was shown that one of the compounds was 
paeonol. When comparing the B B M V results, CM-C and its sub-fractions CM-C 12 
and CM-C 13 all showed over 90% inhibition, while only 70% inhibition was found 
in paeonol (Fig 5.8a). Therefore, other compounds in the sub-fractions CM-C 12 and 
13 should also be responsible for the in vitro effect of CM-C. The red spots showing 
in these fractions were suspected to be the active component. 
In OGTT, CM-C exhibited significant anti-hyperglycaemic effect (Fig。5.5). 
However, as preliminary results, paeonol did not give significant effect (Fig. 5.11), 
though further studies are required to confirm the result. Therefore, other compounds 
in CM-C, probably in CM-C 12 and 13, should also be anti-diabetic in v/vo。 
The reason why we first isolated the compound from sub-fraction CM-C4 
instead of sub-fractions CM-C 12 and 13 was due to the fact that the spot in CM-C4 
had very similar Rf value to that of paeonol reference. I f time permitted, the other 
compound in CM-C 12 and 13 would have also been isolated。 
Apart from compounds found in the present study, it was previously reported 
that another known compound of Cortex Moutan, paeoniflorin, was also anti-diabetic. 
Intravenous injection of paeoniflorin (1.0 to lO.Omg/kg) to STZ-induced diabetic rats 
resulted in lowering basal glycaemia and improvement in intravenous glucose 
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tolerance (Hsu et al., 1997). However, it is important to note that paeoniflorin is a 
monoterpene glycoside, which is structurally different from paeonol. Also, our 
B B M V study (Fig. 5.8a) showed that paeoniflorin significantly increased the glucose 
uptake of BBMV, which was unfavorable for anti-diabetic agent. 
Potential drug development wi th paeonol and CM-C 
Currently, anti-diabetic drugs acting through inhibiting carbohydrate absorption 
from the intestine are usually a-glucosidase inhibitors, such as acarbose and miglitol, 
which inhibit the breakdown of complex carbohydrates into simple ones in order to 
reduce glucose absorption. Therefore, these drugs only work with a meal containing 
complex carbohydrates (Bischoff, 1994; Yee and Fong，1996). On the other hand, in 
our study, CM-C and paeonol were found to improve oral glucose tolerance by 
inhibiting the absorption of glucose by SGLTl, and this could compensate the 
-1 
limitations of current a-glucosidase inhibitors。So a complete inhibition of 
carbohydrate absorption may be achieved by the combined use of a-glucosidase 
inhibitors and compounds inhibiting glucose absorption. 
Although paeonol showed potent in vitro effect in inhibiting intestinal glucose 
absorption, the results were not that promising in preliminary in vivo experiments. 
One of the reasons may be due to the use of y-cyclodextrin since it may affect the 
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action of paeonol. Hence, alternatives such as surfactants (e.g. tween 80) could be 
used to promote the solubility of paeonol. Another reason may be due to the dose of 
paeonol Higher doses of paeonol should be tested. However, its toxicity must be 
taken into considerations. 
Toxicity and adverse effects are important concerns for drug development. 
Previous studies found that the toxicity of paeonol is relatively low (Ji, 1999; Zheng 
et al, 2004). The LD50 of paeonol in mice by intravenous injection, intraperitoneal 
injection and intragastric administration were determined to be 196, 781, and 
3430mg/kg respectively (Harada and Yamashita, 1969). In our study, eight 
consecutive days of oral treatment with 200mg/kg paeonol did not affect the body 
weights of nO-STZ rats, and no obvious adverse effects were observed. However, 
even the drug is probably safe with such doses, long term effects must be fully 
evaluated before consideration of human use. 
A major defect of paeonol is the low solubility in water. Previous studies showed 
that sulphonation on C-4 of paeonol (Fig. 5.10) could highly increase the solubility 
(Wang and Tang, 1983; Wu et al., 2003b). It could also lower the acute toxicity by 
9-fold, although, the analgesic effect was also decreased by 8-fold (Wang and Tang, 
1983). However, the anti-diabetic effects of modified compound need to be farther 
investigated. 
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It is also important to further study the mode of action of paeonol with regards to 
anti-diabetic effect. In vitro studies with B B M V suggested inhibiting intestinal 
glucose absorption as the mode of action. However, this did not exclude any other 
possible mode of action. Therefore, paeonol could be studied with in vitro cell 
models mentioned in chapter 3. 
Apart from paeonol, other substance(s) in CM-C showing potent inhibitory 
effect on B B M V glucose uptake could also be potential candidates for development 
into anti-diabetic agent. Further work should be done for isolation and identification 
of anti-diabetic component(s) in CM-C. 
-4 
Chapter 5 Bioassay-guided Fractionation of Cortex Moutan 162 
Chapter 6 General Discussion 
6.1 Introduction 
In the present study, a detailed systematic approach was used for investigating 
the anti-diabetic effect of Chinese herbs. A screening platform was employed with 
the setup of four in vitro models, BBMV, H4IIE cells, Hs68 cells and 3T3-L1 cells, 
for studying three different mechanisms of anti-diabetic activities: inhibiting 
intestinal glucose absorption, suppressing hepatic glucose production, and enhancing 
glucose uptake of peripheral tissues. For any herbs that showed positive effects in 
vitro, their anti-diabetic effects were confirmed in vivo, using neonatal-STZ diabetic 
rat model. With confirmed in vivo anti-diabetic effect, active components were 
isolated using bioassay-guided fractionation. 
Using such a systematic approach for the study on anti-diabetic effect of Chinese 
herbs was not commonly found in previous studies. Multiple in vitro models were 
used which provided rapid results, attempted to narrow down the number of subjects 
for further in vivo and phytochemical studies. Using this approach, we successfully 
identified anti-hyperglycaemic compounds in the organic extract of Cortex Moutan. 
Since these in vitro and in vivo models were already established, they could form a 
standard screening platform for future studies on potential anti-diabetic agents. In 
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addition, other in vitro models representing different mode of actions, such as growth 
promotion and insulinotropic effect on P-cells, could also be added to this screening 
platform. 
6.2 Summary of Research Findings 
Using the mentioned systematic approach, we investigated the potential 
anti-diabetic effect of a TCM formula "Qi Wei D i Huang Tang" (F2, which originally 
designed for treating diabetic foot ulcer), and also studied the anti-diabetic effect of 
its eight individual herbs. 
From the results of the in vitro studies, F2 was found significantly inhibited 
intestinal glucose absorption and stimulated glucose uptake of fibroblasts and 
adipocytes. However, F2 also showed unfavorable effect in stimulating hepatic 
glucose production in vitro. For its eight individual herbs, all of them exhibited in 
- i 
vitro anti-diabetic effects with at least one of these mechanisms (Table 3.2). Among 
these herbs, Cortex Moutan was the only one showing desirable effects in all in vitro 
experiments, by inhibiting glucose absorption of BBMV, suppressing hepatic glucose 
production and PEPCK activity of H4IIE, and stimulating glucose uptake of Hs68 
and 3T3-L1 cells. Another herb, Rhizoma Alismatis also showed promising effects in 
stimulating cellular glucose uptake, and also inhibiting hepatic glucose production in 
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vitro. Therefore, these two herbs were selected for further detailed in vivo studies. 
In preliminary in vivo studies, F2 did not show any significant effect in lowering 
basal glycaemia or improving oral glucose tolerance in diabetic rats. For Cortex 
Moutan and Rhizoma Alismatis, the aqueous extracts did not show any anti-diabetic 
effect in vivo. 
Although the selected herbs showed negative results in in vivo studies, the in 
vitro B B M V studies revealed that the CHCI3 extract of Cortex Moutan aqueous 
extract had very potent in vitro inhibitory effect on intestinal glucose absorption。 
Therefore, the hexane soluble fraction of Cortex Moutan ethanolic extract (CM-C) 
was studied in vitro and in vivo. CM-C significantly inhibited glucose uptake of 
B B M V in vitro. In vivo studies found that CM-C did not lower basal glycaemia。 
However, CM-C was found significantly improved the oral glucose tolerance of 
diabetic rats. To the best of our knowledge, this is the first report of the 
- 1 
anti-hyperglycaemic effect from crude extract of Cortex Moutan. 
With the promising in vivo results, CM-C was fractionated with bioassay-guided 
fractionation, using B B M V as the in vitro bioassay. At least two compounds were 
found responsible for the in vitro anti-diabetic effect of CM-C. Using mass 
spectrometry and nuclear magnetic resonance techniques, one of these compounds 
was confirmed to be paeonol, which accounted for over 50% of weight of CM-C。 
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Although paeonol is a known compound present in Cortex Moutan, its 
anti-hyperglycaemic activity has never been discussed previously。 
The potential anti-hyperglycaemic effect of paeonol was further studied in vivo 
using OGTT. Our preliminary study showed that paeonol (200mg/kg and 400mg/kg, 
after single dose treatment) slightly improved the oral glucose tolerance, though the 
results did not reach statistical significance. It was suggested that further in vivo 
studies to be repeated to confirm the results, and a range of doses should also be 
used. 
The T C M formula F2 was previously shown to be effective in saving diabetic 
ulcerous feet from amputation (Wong et aL, 2001). In the present study, it was 
hypothesized that anti-diabetic properties might be one of the modes of action. 
Besides, it is also important to know whether F2 possesses any glycaemic effect 
since all diabetic foot ulcer patients are taking western anti-diabetic drugs for the 
- 1 
control of blood glucose. From our results, despite the fact that F2 showed some 
positive effects in different in vitro models (Table 3.2), no positive in vivo effect was 
observed in preliminary studies. The lack of glycaemic effect of F2 had to be further 
confirmed by in vivo and clinical studies. 
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6.3 Limitations and Improvements 
.Since all of the herbal components in F2, including Cortex Moutan and Rhizoma 
Alismatis, were commonly used in T C M formulae for treatment of diabetes (Table 
1.3, Wu and Ren, 2002), the negative animal findings on F2 and the two herbs 
somehow contradicted with the traditional uses of these herbs. However, it should be 
noted that in TCM theory, blood glucose is not a measuring parameter in the 
treatment of diabetes. Instead, the use of TCM more emphasizes on relieving the 
symptoms of the disorder and restoring the functions of organs and the inner-balance 
of body. Therefore, a herb being commonly used in anti-diabetic TCM formulae does 
not necessarily mean that it can immediately lower plasma glucose level after 
administration. Instead, other possible actions such as restoring and protecting p-cells 
functions may apply, which required weeks or months of treatment in order to detect 
the effects (Jia et al�, 2003). 
-1 
In contrast to the TCM approach on diabetic treatment, most scientific 
anti-diabetic researches including this project target on finding anti-diabetic agents 
that can lower plasma glucose level and improve glucose tolerance. The difference 
between the approaches on diabetic treatment might be responsible for our negative 
in vivo findings with commonly used anti-diabetic Chinese herbs. 
Although the present project suggested the use of multiple in vitro models as a 
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screening method in anti-diabetic researches, these study models are all looking at 
actions in a relatively short period of time, ranging from seconds to hours. Since 
T C M may work in a slow manner, these in vitro models would have neglected such 
chronic effects. I f such long-term effects are of interest, in vivo studies would be 
more appropriate as longer experimental period and investigations on complex 
pharmacological actions are permitted。 
In accordance to the usual traditional use of Chinese medicine, (i.e. by boiling 
the herb wi th water and drinking the water extract), aqueous extracts of the herbs 
were studied in this project. It was found that the aqueous extracts of Cortex Moutan 
and Rhizoma Alismatis did not have any anti-diabetic activities in v/vo。However, in 
subsequent study using the organic extract of Cortex Moutan, significant in vivo 
anti-hyperglycaemic effect was observed。This finding revealed that some active 
components in herbal medicine might not have been dissolved in water. Although 
- 1 
studies on organic extract of herbal medicine would not explain the traditional use of 
Chinese herbs, it does allow non-polar active components to be discovered. 
The HPLC analysis on simple sugars content in herbal extracts also revealed an 
issue which is obvious but often overlooked in anti-diabetic TCM researches: 
aqueous herbal extract could contain large amount of sugars without any therapeutic 
value, quenching the effect of active components, or even providing false positive or 
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false negative results in experiments. For example, in Radix Astragali extract, more 
than half of the weight is composed of simple sugars. Therefore, the existence of 
these sugars should always be noted and preferably controlled during anti-diabetic 
T C M research. 
6.4 Future Directions 
There are two major directions for furthering this project: to identify new 
anti-diabetic herbs or herbal formulae, and to continue the study on the 
anti-hyperglycaemic effects of paeonol and isolate other active components in Cortex 
Moutan extract. 
In order to further the search for anti-diabetic herbs, potential herbs should be 
chosen according to their traditional uses with regards to anti-diabetic effect 
(ethnopharmacological approach), which helps to reduce the number of herbs that 
need to be screened and results in a greater success rate than by random selection and 
mass bioscreening (Famsworth, 1994). As Chinese herbs are usually used in mixture 
in formulae rather than as single herb, the possible synergistic effects among 
different herbs would also need to be considered. Therefore, both TCM formulae and 
individual herbs should also all be studied. Herbs that have no effect could be taken 
out from formulae, while individual herbs that originally not in the formulae but with 
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promising effect could be added. Therefore, new anti-diabetic formulae could be 
invented based on scientific research. 
On the other hand, since Cortex Moutan organic extract showed promising 
anti-hyperglycaemic effect, it should be further investigated using pharmacological 
and phytochemical studies. The potential use of paeonol as an anti-diabetic agent 
should also be further investigated 
6.5 Conclusion 
A study platform with various in vitro models was established for the screening 
of potential anti-diabetic agents with different mode of actions。Although in vitro 
studies suggested potential anti-diabetic effects of F2 and its individual components, 
the effects were not found with animal studies. Cortex Moutan and Rhizoma 
Alismatis aqueous extracts did not possess in vivo anti-diabetic effects. In vivo 
effects of F2 required further confirmation, though preliminary tests did not show 
any potential activities. 
Hexane soluble fraction of Cortex Moutan ethanolic extract potently inhibited 
intestinal glucose absorption in vitro, and showed significant anti-hyperglycaemic 
effect in vivo. Paeonol was responsible for part of the activity. This is the first report 
of the anti-hyperglycaemic effect of Cortex Moutan crude extract and paeonol. Their 
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pharmacological and phytochemical properties, as well as the potential of being new 
anti-diabetic agents should be further explored. 
-i 
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